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ABSTRACT 
Acetylation (ac) and tri-methylation (me3) of lysine number 27 on histone 3 (H3K27) play a 
very important role for early development and differentiation in embryonic stem cells, and often 
determine which cell type- specific processes are silenced and activated.  H3K27 marked genes 
are often aberrantly expressed in adult cancers.  When H3K27 is tri-methylated (H3K27me3), it 
is an indicator for a transcriptionally inactive gene.  When H3K27 is acetylated (H3K27ac), it is 
an indicator for a transcriptionally active gene.  This study focused on determining the binding 
site for H3K27ac within the mesoderm induction early response 1 (MIER1) protein, a fibroblast 
growth factor (FGF) inducible early response gene that is known to recruit chromatin modifiers 
and transcription factors for gene repression.  The first 83 amino acids of MIER1 had been 
previously shown to bind H3K27ac.  Alignment verification of the first 83 amino acids of 
MIER1 between different species revealed highly conserved sequences that represent the 
potential binding site. Site directed mutagenesis was employed to mutate highly conserved 
hydrophobic aromatic amino acid sequences in the full-length protein, as well as create deletion 
constructs.  The mutated MIER1 proteins were then tested against wild type MIER1 protein for 
their ability to bind H3K27ac in peptide pull down assays.  The results of this study have 
localized the C-terminal end of the 83 amino acid binding site to amino acids 36-50, and have 
shown that the amino acid sequence 
38
TLE
40
 is required in part for binding.   
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Chapter 1- Introduction 
 
1.1 General Introduction 
 
1.1.1 Structure and Function of Chromatin  
 
Chromatin in a eukaryotic cell’s nucleus consists of DNA and proteins.1,2  The DNA is 
tightly wrapped around histone proteins which form the nucleosome structure.
1
  The 
nucleosome consist of 146 base pairs of DNA wrapped around the core histone proteins.  
There are four core histones: histone 2A (H2A), histone 2B (H2B), histone 3 (H3) and histone 
4 (H4).  The histones are organized into an octamer with two copies of each, as shown in 
Figure 1.1.   All the core histones are organized in a fold like manner of three helices 
separated by two short strap loops, which are then formed into heterodimers by folding the 
helices into a “handshake motif” or “helix-strand-helix” motif.  These helices are held by the 
linker histone 1 (H1).   This alignment of the histones and DNA in the nucleosome is a major 
factor in the DNA accessibility and other histone-histone interactions.
1–4
  Another important 
feature on the core histones is the unstructured N-terminal histone tails that protrude from the 
nucleosome.   These histone tails are made up of varying sequences of amino acids for 
histones H1, H2A, and H2B.  However, the histone tail amino acid sequences from H3 and H4 
are nearly identical in all eukaryotes, indicating that sequence conservation is essential for 
function. 
2
  The histone tails are often subjected to post translational modifications (PTMs).  
There are many different PTMs, and examples of the most common modifications include: 
methylation, acetylation, phosphorylation, ubiquitination, sumoylation, and citrullination and 
is shown in Figure 1.1. 
5, reviewed in 6
  These PTMs serve as markers for transcriptional 
regulation as they dictate whether the DNA is accessible or not for undergoing transcription 
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from the histone proteins, and also serve as markers in various histone-histone interactions.  
The PTMs ultimately act as mechanisms by which chromatin modification occurs within the 
cell.  The different PTMs will be discussed in the next section.   
 
1.1.2 The Histone Code 
 
For a long time the functions of histone proteins were not known, nor was the significance 
of the PTM marks on the histone tails.   Historically it was believed that the nucleosome core 
was unchanging, and the positively charged acetyl groups were responsible for loosening the 
DNA from the histone by neutralizing the charge on the negatively charged DNA, thus 
allowing the DNA to be transcribed. 
7,8
  It is now known that within the cell, the nucleosome 
core is perpetually adjusting in response the cells environment. An example that changes the 
nucleosome structure is the different PTMs on histone tails that are a signal for gene 
activation, gene inactivation, recruiting histone modifying complexes, and various other 
complexes and signals, thus acting as a “code” for what is to happen in that particular site.  
Drs. Strahl and Allis named this “code” the “histone code” in 2000.8  They proposed that there 
is a certain “language” of multiple modifications that is encoded onto the histone tail domains 
that is read by proteins to cause specific downstream functions.
8,9
  The “histone code” that is 
printed on the N-terminal tails, is crucial since the enhancer DNA itself is not responsible for 
the initiation of gene expression in the cell.  Instead, multiple transcription factors binding to 
the enhancer DNA mediates the recruitment of chromatin modifiers and other transcription 
complexes that generate additional regulatory information from the “histone code”.  
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Figure 1.1: Histone structure 
a. There are two copies of each of the four core proteins: H2A , H2B, H3, and H4 forming an 
octamer. The DNA is wrapped around the histone proteins (shown in black) to form the 
nucleosomes. The N-terminal tails of core histones are shown in red protruding from the 
histone proteins.   B. The N-terminal tails protruding from the core histones are broken down 
into the known amino acids that can be post transitionally modified with the position number 
of the amino acid (aa) beside it.   Lysines (K) are potentially acetylated/deacetylated by 
histone acetyltransferases (HATs) and histone deacetylases (HDACs).   The lysine 18 on 
histone 3 is shown to be modified by HATs or HDACs in this schematic.  Reprinted from 
Nature Reviews Cancer, Paul A. Marks, Richard A. Rifkind, Victoria M. Richon, Ronald 
Breslow, Thomas Miller & William K. Kelly.  Histone deacetylases and cancer: causes and 
therapies, pp. 194-202. Copyright 2001, with permission from RightsLink / Nature Publishing 
Group)
10
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Since the environment within the cell is constantly changing, and DNA transcription does not 
need to continuously occur, the histone code is only temporal and each modification occurs 
only when needed.  The “DNA code”, however, is permanent and contains all the information 
for printing and manufacturing the “histone code”. 11 
To access the information preserved on the DNA certain histone modifying proteins or 
protein complexes are recruited to each particular modification on the histone tail to “read” 
what the modification is and then begin downstream effects.  Other modifying complexes 
could be recruited to “write” or “erase” modification by adding or removing a PTM, 
respectively.  These three modifying complexes work together in regulating transcription of 
each respective target gene. 
12,13
 
 
1.1.3 Writers and Erasers of Methylation 
 
There are different readers, writers and erasers for the various types of PTMs on histone 
tails. But there are only a few amino acids that are covalently modified.  These are lysine (K), 
arginine (R), serine (S), threonine (T), tyrosine (Y), histidine (H) and glutamic acid (E).
14
  The 
most common covalent modification that occurs is methylation and acetylation on lysines.
15
  
The acetylation modification on histones was first identified by Alfrey in 1964 as a potential 
regulator of RNA synthesis.  Scrutinization of this process since then has led to the discovery 
that lysine acetylation plays a key role in transcriptional activity: essentially genes being 
turned “on”. 14,16  The methylation modification on histones was first identified by Murry in 
1964 but the significance of the modification was not known until decades later.
17
  More 
recent discoveries have found that lysine methylation is often correlated with transcriptional 
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repression and condensation of the chromatin: essentially the genes being turned “off”.  
However, depending on the location of the methylated lysines, this modification can be an 
indicator for gene activation, which will be discussed further on in section 1.1.6.
17,18
 
Histone lysine methylation plays an essential role in chromatin organization and function. 
This modification is connected to many processes including genomic imprinting, chromosome 
X- inactivation, heterochromatin formation and transcriptional regulation.
19
  The writers of 
histone methylation are histone lysine methyltransferases (HMTs or KMT’s).  HMTs add 
methyl groups to lysine residue from the co-factor S-adenosylmethionine (SAM) onto the 
amine of the specific lysine residue, as shown in Figure 1.2.  The ε-amino group can be mono-
,di-, or tri-methylated, and each methyl group added can change the function.
19
  Methylation 
causes a condensed DNA chromatin structure that is referred to as heterochromatin. Other 
than the disruptor of telomeric silencing-1- like (Dot1L), all HMTs use an evolutionally 
conserved SET (SU(VAR)3–9, enhancer-of-Zeste, Trithorax) domain for lysine methylation.20  
Compared to other histone modifying enzymes, HMTs often methylate specific lysine 
residues.  There are around 10 human methyltransferases, and such examples of these are: 
SET9, SET1, MLL, and SMYD3 methylate H3K4; G9a, EHMT1/2, and SUV39H1/2 
methylate H3K9; G9a and EZH2 methylate H3K27; NSD1; SETMAR methylate H3K36; 
DOT1L methylates H3K79; SET8 and NSD1 methylate H4K20. 
19–21
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Figure 1.2: Lysine Methylation 
  
The writers of histone methylation are histone lysine methyltransferases (HMTs or 
KMT’s). They add a methyl group to lysine residue from the co-factor S-adenosylmethionine 
(SAM) onto the amine of the specific lysine residue. (Reprinted from ATDbio, Epigenetics. 
Copyright. 2005-2015, with permission from ATDbio Ltd)
22
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Histone lysine demethyltransferases (HDMs) are responsible for removing the methyl 
group from the lysine residue.  The HDMs are divided into two families: lysine-specific 
demethylase (LSD) proteins and Jumonji domain (JMJD) containing proteins. The JMJD 
family includes: FBXL, JMJC1-3, PHF, JARID, and other JMJD subfamily proteins.
19,20
   
LSD proteins are linked to different modifying complexes involved in transcription, 
heterochromatin spreading, and stress-induced responses.  LSD1 demethylates 
H3K4me2/me1, H3K9me1/2, and other non-histone substrates, such as p53.  FBXL proteins 
are involved in regulating transcriptional elongation by demethylating H3K36me1/2.  The 
JMJD1 proteins demethylate genes related to tumor suppression, androgen receptor targeting, 
and thyroid receptor responding by demethylating H3K9me2. 
20
  JMJD2 proteins remove 
methyl groups from H3K9me2/3, which is associated with transcriptional elongation and 
transcriptional repression.  JMJD3 proteins are specific to demethylating H3K27me2/3, which 
is essential for normal development, cell fate decision, and halting pluripotency.  PHF proteins 
demethylate H3K9me2 and H3K27me2 repressing marks.  JARID proteins demethylate the 
coding regions of transcribed genes on H3K4me2/3 and have also been known to work as a 
transcriptional co-repressor. Different point mutations found in X-linked mental retardation 
are linked to JARID activity. 
23
  JARID2, also known as Jumonji, is phylogenetically related 
to the JARID1 family, but no related enzymatic activity has been shown. 
19,20
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1.1.4 Writers and Erasers of Acetylation 
 
Histone acetyltransferases (HAT’s or KAT’s) are the writers of acetyl modifications on 
lysines.  They neutralize the positive charge on the ɛ-amino group by transferring an acetyl 
group from acetyl-CoA onto the lysine residue.  This leads to accessibility of the chromatin 
for transcriptional activation, as shown in Figure 1.3.  This accessible state of chromatin is 
also referred to as euchromatin.
21
  The different types of HATs that modify lysines are 
classified by their catalytic activity.  These include:  Gcn5 N-acetyltransferases (GNATs) 
(which contains Gcn5, PCAF, Elp3, Hat1, Hpa2 and Nut1), the Morf, Ybf2 (Sas3), Sas2 and 
Tip60 (MYST) HATs, and other proteins including p300/CBP (CREB-binding protein).  Taf1 
and other nuclear receptor co-activators, have been reported to show HAT activity, but do not 
contain true consensus HAT domain. 
24,25
  While acetylation of histone tails is mostly linked 
to transcription, acetylation of non-histone substrates has also been linked to DNA repair and 
replication.
6
   
Histone deacetylases (HDACs) are the erasers of the acetylation modification by removing 
the acetyl motif from the ε-amino group of the lysine.  The removal of the acetyl group which 
is known as N
ε
-deacetylation
26
 is, shown in Figure 1.3.  This causes a decrease in the space 
between the nucleosome and DNA that is wrapped around it.  This diminishes accessibility for 
transcription factors, and leads to transcriptional repression.  There are 18 different HDACs 
classified into two families: the classical and silent information regulator 2 (Sir2)-related 
protein (sirtuin), and four classes depending on their similarity of yeast proteins.  Class I 
includes: HDAC 1, HDAC 2, HDAC3, HDAC8 and are similar to the deacetylase yeast 
protein RPD3.  Class II includes: HDAC 4, HDAC 5, HDAC6, HDAC 7, HDAC 9, 
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Figure 1.3: Lysine Acetylation and Deacetylation 
HATs or KATs write the acetyl modification on specific lysines by transferring an acetyl 
group from acetyl-CoA to the lysine residue on the ɛ-amino group, neutralizing the positive 
charge.  HDACs remove the ε-amino group from the lysine and release acetate.  (Reprinted 
from International journal of cell biology, Kim, Go-Woon Gocevski, Goran, Wu, Chao-Jung 
Xiang-Jiao Yang, Dietary, Metabolic, and Potentially Environmental Modulation of the 
Lysine Acetylation Machinery, pp. 351-365. Copyright 2010, with permission from Elsevier) 
27
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 HDAC 10 and are similar to the yeast protein HDCA1. 
28
  HDAC6 and HDAC10 have two 
active sites and therefore often classified as class IIA.  In the catalytic center of HDAC11 are 
conserved residues found in both class I and class II of HDACs.  Therefore, it is sometimes 
placed in class IV.  These deacetylases are known to be inhibited by vorinostat 
[suberoylanilide hydroxamic acid (SAHA)] and trichostatin A (TSA).   Class III in mammals 
contain deacetylating sitrunis proteins (SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, SIRT7) 
and Sir2 in yeast proteins.
26,28,29
   
HDACs need to be able to enter the nucleus because often their main target protein or 
protein complexes are found in the nucleus.  HDACs do this through their nuclear localization 
signal (NLS) or by co- localization in conjunction with other proteins HDACs.  Most HDACs 
contain a NLS, and are found in the nucleus. However, some HDACs are found in the 
cytoplasm, depending on their different catalytic domains.
29
  Class I HDACs are found almost 
exclusively in the nucleus. 
HDAC1 and HDAC2 are exclusively nuclear, since they do not have a nuclear export 
signal (NES).  HDAC3, however, contains NLS and a NES.  This suggests that HDAC3 can 
be recruited to the cytoplasm.  Class II HDACs are able to exit and enter in and out of the 
nucleus in response to certain cellular signals, however, HDAC6 is predominantly found in 
the cytoplasm.  Class IV is generally found in the nucleus; but HDAC11 has been shown to be 
co-localized to the cytoplasm with HDAC6. 
29,30
 
Within the past decade, HDAC inhibitors have become widely produced and advanced into 
clinical drugs for the treatment of certain cancers, Alzheimer’s, arthritis, and even anti-latency 
therapy for persistent human immunodeficiency virus type 1 (HIV-1) infection.
31–34
  Because 
HDACs play an important role in regulating cellular gene expression, differentiation, 
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development, and the maintenance of cellular homeostasis, this altered expression of HDACs 
often plays an active role in tumor growth and progression.  Aberrant expression of HDACs 
activity has been found in tumor samples.  Different studies have found that there is an 
increase in HDAC1 expression in gastric, prostate, colon, and breast carcinomas. Other 
studies have found that the over-expression of HDAC2 has been noted in cervical, gastric 
cancers, and in colorectal carcinoma.  Also, high levels of HDAC3 and HDAC6 have been 
reported to be expressed in colon and breast cancer specimens.
35–41
   
Applying HDAC inhibitors towards classes of HDACs that have known involvement in 
modifying complexes could be an important application for clinical treatments.  Class I 
HDACs have been reported to be associated with at least four major chromatin modifying 
complexes that control gene silencing.  HDAC3 is recruited uniquely to the silencing mediator 
of retinoic acid and thyroid hormone receptor (SMRT) and  nuclear receptor co-repressor 
(NCoR) repression complexes.
42,43
  HDAC1 and HDAC2 are activated through recruitment 
into several co-repressor complexes including the Sin3A
44
, co-repressor for element-1-
silencing transcription factor (CoREST)
45
, and nucleosome remodeling deacetylase 
(NuRD)
46,47
 complexes.  
One study found the need for the compound inositol phosphate: D-myo-inositol-1,4,5,6-
tetrakisphosphate [Ins(1,4,5,6)P4] in the binding pocket of HDACs to act as a conserved 
regulator of Class 1 HDACs and their recruited repressor complex.
31
  They found that HDAC3 
forms a complex with the extended SANT domain from the SMRT co-repressor.
48
  Also, the 
interaction between HDAC3 and the SMRT-SANT domain has been shown to require the 
presence of Ins(1,4,5,6)P4.  By using sequence conservation, other class I HDAC complexes 
are thought to bind inositol phosphates.  The interaction between HDAC1 and metastasis-
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associated protein 1 (MTA1) from the NuRD complex uses the MTA1’s EGL27 and MTA1 
homology 2(ELM2) and SWI3, ADA1, NCoR, TFIIIB (SANT) domains.  The structure 
reveals that this complex also has an inositol phosphate binding pocket at the interface 
between the MTA1- SANT domain and HDAC1.  The HDAC1:MTA1 structure provides 
insight into how the combination of the ELM2-SANT domains are able to recruit histone 
deacetylase enzymes.  Together, the two domains make very extensive interactions with 
HDAC1 by wrapping completely around the catalytic domain and covering both the carboxy- 
and amino-terminal ends.  This suggests that the two domains might be a common feature in 
class I HDAC: co-repressor complexes and could be used in the future for developing specific 
inhibitors to mimic the inositol phosphate interaction with the protein and the ELM2-SANT 
domains. 
 
1.1.5 Reader Domains and Their Targets 
 
Readers of modified amino acid residues have conserved effector domains within proteins 
that recognize and bind to specific modifications and cause downstream effects that will either 
stabilize the chromatin or recruit other complexes to further modify the chromatin.  Reader 
proteins typically use a cavity or surface groove to hold the modified histone residue, and they 
determine what the modification is, and/ or determine the number of modifications.  For 
example a reader protein may determine whether the amino acid is mono, di- or tri-
methylated.
14,49
  These domains include chromodomains, bromodomains (BRD), WD40 
repeats, tudors, plant homeodomain (PHD), and malignant brain tumor (MBT).
9,50
   BRDs 
recognize the acetyl modification on the ε-N-acetylated lysine residues and some PHD fingers 
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can recognize various acetylated lysines.
15,51
  Chromodomains, WD40 repeats, tudors, certain 
PHD fingers, and MBT domains recognize methyl modification on specific lysine 
residues.
14,49
  The downstream effects caused by reader proteins and their respective domains, 
along with their associated complexes will be discussed further on in this section. 
 
BRDs selectively target acetylated lysines.  In humans, there are over 40 known proteins 
that contain more than 60 different BRDs.  BRDs fold into 120 amino acid, a four α helix 
structure (αZ, αA, αB and αC), which is linked by loop regions of varying length (ZA and BC 
loops) where the acetyl binding site is located.  BRD containing proteins often cooperate in 
chromatin remodeling complexes, transcriptional control, and methyl or acetyltransferase 
activity.  The organization of BRD-containing proteins is evolutionarily conserved, and the 
BRD domain is often found with other epigenetic reader domains.  Observed combinations 
include the PHD, as well as multiple BRDs, and various other domains that are known to 
moderate protein interactions, an example is the bromo-adjacent homology (BAH) domain.
52–
55
  
The recognition of acetylated histones through the BRD uses a small selection of conserved 
amino acids.  One study used site-directed mutagenesis to determine which of these amino 
acids specifically bind acetylated lysine residues found in a cluster of hydrophobic amino 
acids on the inner structure (often called a hydrophobic pocket) of a BRD.
56
  They mutated 
amino acids 
809
Y, 
802
Y, 
760
Y and 
752
V in the BRD of the HAT co-activator PCAF (p300/CBP-
associated factor).  These are highly conserved hydrophobic and aromatic amino acids 
throughout the BRD family, and indicate that they are an important feature of the BRDs 
binding ability.  They found that substitution of alanine for 
809
Y completely obliterated 
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binding to the lysine-acetylated H4 peptide, whereas the Y802A, Y760A and V752A mutants 
had significantly reduced ligand-binding affinity.  In order to determine if the mutations 
disrupted the overall BRD fold, they compared the 3D structure using 15N-HSQC 
(Heteronuclear Single Quantum Coherence) spectra of the mutants to that of the wild-type 
protein.  The Y809A mutant was only affected for a few residues near the mutation site.  
However, mutations of the other residues in the hydrophobic binding pocket caused greater 
changes in the protein conformation, particularly in the ZA loop.  Nuclear magnetic resonance 
(NMR) structural analysis and mutagenesis have shown that certain amino acids (
809
Y), are 
essential for the BRD  interaction with the acetyl group of acetylated lysine, and other amino 
acids (
802
Y, 
760
Y and 
752
V) imply both structural and functional roles in the recognition.
56
  
The PHD fingers are readers of PTMs and were first discovered by Schindler in 1993: who, 
noticed a stretch of cystines that were always between two plant homeodomains in the protein 
HAT3 in Arabidopsis thaliana.
57
  The PHD finger motif is about 60 amino acids in length, 
and resembles the metal binding RING domain, which binds four cysteines, one histidine, 
three cysteines (C4-H-C3) and binds two Zn
+2 
.  In yeast and fly the PHD proteins are nuclear 
and bind DNA or chromatin, to mediate control over transcription, and the chromatin 
structure.  As with other writers or erasers, reader containing proteins often target specific 
sites.  For example, PHD containing proteins can be sorted into two categories depending on 
what they have been shown to target.  The first category of PHD fingers target H3K4me3 and 
unmodified H3.  The second category of PHD fingers target H3K9me3, and various acetylated 
lysine residues on H3 and H4
reviewed in 51,57–60
 
Chromodomains are readers of methylated lysines; they are folded into three anti-parallel 
beta strands against a C-terminal alpha helix that mediate protein–protein and/or protein–
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nucleic acid interactions.  The chromodomain is evolutionally conserved and is a member of 
the OB-fold class found in DNA binding proteins of archaea, bacteria and eukaryotes.  
Chromodomain proteins are divided into three classes: proteins with a single chromodomain, 
proteins with an N-terminal chromodomain with a structurally similar C-terminal chromo 
shadow domain, and proteins with paired tandem chromodomains.  The chromodomain binds 
to the methylated residue as a beta strand in a conserved groove on the surface of the 
chromodomain, which forms a beta sandwich.  Different proteins containing chromodomains 
target certain lysine residues such as: CHD1 on H3K4, HP1 on H3K9 and Polycomb proteins 
on H3K27. 
58,61
 
Tudor and MBT domains have also been shown to recognize the methyl group on lysine 
residues, and are known as the ‘royal family’ along with chromodomains for their similar 
structure and target residues.  Tudor domains have been shown to bind to H3K4, H3K9 and 
H4K20.  MBT domains have been shown to target H3K4 and H4K20. 
reviewed in 6,14,50
 
Often reader effector motifs are found in a complex of proteins that control epigenetic 
regulation along with writer and eraser proteins; this allows for a modification to be analyzed, 
written on or removed, thus controlling the gene activity surrounding that histone 
modification.  Proteins with BRDs, chromodomains, PHD and MBT domains have been 
shown to act together with other chromatin modifiers in complexes to remodel the chromatin.  
There are many well-known examples of these complexes.  The NuRD complex which is 
involved in ATP-dependent chromatin remodeling and histone deacetylase activities 
contains: the histone deacetylase proteins HDAC 1/2 , the histone-binding proteins RbAp46 
and RbAp48, the MTA1 (or MTA2 / MTA3), the methyl-CpG-binding domain protein 
MBD3/2, and the chromodomain binding protein CHD3/CHD4/CHD5. 
62,63
  The NURF 
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complex is an ISWI-containing ATP-dependent chromatin-remodeling complex.  The NURF 
subunit BPTF (BRD and PHD finger transcription factor), associates with chromatin and 
recruits the associated ATPase, SNF2L (also known as ISWI and SMARCA1), to the HOXC8 
promoter.  This complex is recruited to H3K4me3 to maintain Hox gene expression patterns 
during development.
60,64
 The co-repressor NCoR1 remodeling complex (contains TIFβ protein 
with a BRD and PHD finger) promotes heterochromatin formation by interacting with the 
heterochromatin chromodomain containing protein HP1.
65
  There is a known 
REST/CDYL/G9a complex where CDYL(chromodomain protein, Y like) bridges 
REST(repressor for element-1-silencing transcription factor), a neuronal gene repressor and 
histone methyltransferases for gene repression and suppression of cellular transformation.
66
 
1.1.6 Known Methylated and Acetylated Lysine Residues and their Functions 
 
Acetylated lysine residues distinguish transcriptional activation.  However, acetylation of 
specific lysines on a particular histone tail does not seem to be as important compared to the 
overall acetylation level of histone proteins.  Although, HATs are not residue specific, HMTs 
are often lysine specific to what they methylate.  HATs are able to acetylate many different 
residues on histone proteins, and are limited to which histone they can acetylate.
25,67
  HAT 
enzymes have tissue specific functions, and different HAT enzymes will target different lysine 
residues at stage specific developmental times.
24
  Acetylated lysines can also act as active 
enhancers elements in ES cells for starting tissue-specific patterning.
68
 
Lysine residues that are methylated can be an indicator for transcriptional activation or 
repression.  Genes that are methylated at lysine 4 (H3K4), lysine 36 (H3K36) and lysine 79 
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(H3K79) of histone H3 are indicators of active chromatin. Whereas methylation at lysine 9 
(H3K9) and lysine 27 (H3K27) of histone H3 and methylation at lysine 20 of histone H4 
(H4K20) are indicators of repressed chromatin.  Di-methylation at H3K4 can indicate both 
inactive and active genes, whereas tri-methylation is only found on active genes.
19
  The HMT 
that adds the methyl modifications are also often lysine specific as previously stated.  The 
levels of methylated lysines can also vary depending on the stage of development and the 
tissue specificity in which they are located.
69,70
 
 
1.1.7 H3K27 Acetylation and Methylation 
 
Histone 3 lysine 27 can be acetylated, mono-, di-, and tri-methylated.  However, the acetyl 
or methyl modifications are placed separately, and do not occur at the same time.  The 
acetylated modification on lysine 27 was first discovered in yeast and has since been studied 
in mice and humans.
71,72
   
Acetylation of H3K27 (H3K27ac) has been shown to be associated with many active 
genes.  One study found that the trithorax proteins (TRX), is required for H3K27 acetylation.  
The TRX proteins and their founding member trithorax belong to a collection of proteins that 
are responsible for the maintenance of gene expression.  They are typically found in activating 
gene expression.
73
  Myeloid/lymphoid or mixed-lineage Leukemia (MLL), is the human 
homolog of trithorax.  One study found that trithorax associates with CBP and was required 
for maintenance of transcriptionally active states and thus repressing Polycomb silencing.
74
 
This will be discussed further on in the section.  H3K27ac is found in high levels in the early 
stages of Drosophila embryos and begins to decline after four hours as the opposite 
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methylation modification occurs and H3K27me3 is increased.
74
  The same study found that 
knockdown of the methyltransferse E(Z), which is responsible for methylating H3K27, 
decreases H3K27me3 and increases H3K27ac in bulk histones. Moderate over-expression of 
CBP in vivo caused a global increase in H3K27ac and a decrease in H3K27me3.  This 
decrease in methylation levels increased Polycomb mutants due to lack of methyl dependent 
silencing.  The TRX over-expression also led to an increase in H3K27ac and then a decrease 
in H3K27me3, resulting in defects in Polycomb silencing.
74
   
H3K27ac acts as an important enhancer mark that can determine active from poised 
enhancer elements.  When enhancer proximal genes lack H3K27ac enrichment, they display 
lower expression levels compared to the average enhancer proximal gene.  This modification 
can be written by the CREB binding protein (p300/CBP), and is associated with active 
promoters in mammalian cells.
68
   
The other PTM methylation, particularly tri-methylation on H3K27 is a repressive 
identifier of transcription. H3K27me3 is important in the differentiation of cells.  Tri-
methylation is catalyzed by the Polycomb recessive complex 2 (PRC2) which is part of the 
Polycomb group (PcG) proteins. The repression of most developmental gene regulation 
through histone modifications requires the PcG proteins.  They are highly conserved 
transcriptional repressors and are required for correct body patterning since they control Hox 
gene expression.
75,76
  Components of PRC2 are essential in the earliest stages of vertebrate 
development.  The Polycomb proteins were first studied in Drosophila and through gene 
deletion studies.  In Drosophila the core subunits are: enhancer of zeste [E(Z)], suppressor of 
zeste (Su[z]12), extra sex combs (ESC), and multicopy suppressor of IRA1 (MSI1).
77
  In 
humans the PRC2 core components are: enhancer of zeste homolog 1/2 (EZH2), suppressor of 
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zeste 12 (SUZ12), embryonic ectoderm development (EED), and retinoblastoma associated 
protein 46/68 (RbAp46/48).  EZH2 is a H3K27 methyltransferse, and SUZ12 is required for 
the methyl activity of EZH2.
78
  The EED subunit is a reader of the methyl modification on 
H3K27, and RbAp46/48 has acts as a histone chaperone with H3.
49,78
   
It has been shown that PRC2 and Polycomb proteins are essential for development, 
(especially in homeotic conversions) and PRC2 is an important regulator in many cell types.  
Some cell types regulated by PRC2 include human stem cells; adult and embryonic (ES), 
neural, epidermal and haematopoietic. In human ES cells PRC2 works with pluripotency 
factors Oct4, SOX2 and NANOG to stop lineage-specific genes and keep the pluripotent 
state.
79
  Most H3K27me3 targets of PRC2 are specified in stem cells, and early 
embryogenesis.  They often target developmental processes such as gastrulation, mesoderm 
formation and neurulation, and either the methylation modifications are maintained on 
H3K27me3 or they are lost upon transcriptional activation during development.
81
   
In mouse ES cells it was found that 512 genes bound by H3K27me3 are occupied by 
components of the PRC2 complex.
81
   These regions show a notable enrichment in genes 
related to transcription and development.  The transcription and development processes 
include: organogenesis, morphogenesis, pattern specification, neurogenesis, cell 
differentiation, embryonic development, and cell-fate commitment. Also, the target genes 
within development and transcription functional groups overlap, which indicates that most of 
the PcG target genes are for transcription factors and have crucial roles in a variety of 
developmental processes.
81
   
In different species it has been shown loss of PRC2 results in non functioning embryo or 
death.   Using temperature sensitive Drosophila mutants of E(Z), that loss of functional E(Z) 
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caused a loss of PcG protein binding to the chromosomes, and deprived histones of K27 
methylation.  It has also been shown that an HMTs negative SET domain mutant Drosophila 
E(Z) does not repress HOX genes in vivo, which implicates that H3K27 is the essential 
substrate that PRC2 modifies for Polycomb repression in differentiation.
77,82
  In mice removal 
of PRC2 and other PcG proteins is lethal after implantation of the embryo.
83
 
 
The role of tri-methylated and acetylated H3K27 is also important in the developmental the 
bithorax complex (BX-C).  The BX-C in Drosophila is a group of homeotic genes that give 
rise to body segmentation plan.
84
  The expression of each gene is governed by cis- regulatory 
domains with one for each parasegment.  Repression of the domains is dependent on the PcG 
proteins which controls H3K27me3 of H3.  Parasegment-specific indication of PcG function 
on H3K27me3 locations across the BX-C in successive parasegments shows a "stairs" pattern 
that revealed the boundaries of the BX-C regulatory domains function.  Acetylated H3K27 is 
broadly enriched across active domains, in a pattern harmonious to that of H3K27me3.
84
 
H3K27me3 and H3K27ac are mutually exclusive, but either can occur together with the 
modification H3K4me3 in regions referred to as bivalent domains.
74
  Bivalent domains occur 
in nucleosomes with two modifications simultaneously occurring.  Bivalent domains often 
occur in the promoter of specific transcription factors, and are thought to keep the genes 
poised in order to respond to developmental cues.  These cues dictate whether or not the 
targeted genes will then be activated or repressed depending on the received signals.
85
  These 
domains can also occur in adult tissue as well.
86
 H3K27me3 can occur in large domains 
spanning several hundred of kilobases or found individually on genes. It has been found that 
these domains can be associated with gene families, such as the Hox gene clusters.
79
 
  
21 
 
1.2 Mesoderm Induction Early Response 1: MIER1 
 
1.2.1 MIER1 
Mesoderm Induction Early Response 1 (MIER1) was first identified in Xenopus laevis 
(Xmier1) as a fibroblast growth factor (FGF) activated gene.  Its expression levels were found 
to increase after  the induction of mesoderm differentiation of FGFs in Xmier1.
87
  It is highly 
evolutionarily conserved between species, and a later study found the amino acid sequence of 
Xenopus laevis and human ortholog shared 91% similarity.  There is also a 95% amino acid 
sequence similarity between the human and mouse orthologs.  The SANT domain of MIER1 
between the human, mouse and Xenopus orthologs are idenitical.
88,89
  The human MIER1 gene 
is located on chromosome 1p31.2, spans 63 kb, and consists of 17 exons.  It encodes six 
protein isoforms.  Through different splicing of a facultative intron, the human MIER1 gene 
produces distinct carboxyl termini isoforms (α and β), and will be discussed in the next 
section.
90
  During early embryo development, Xmier1 mRNA levels are evenly expressed in 
early cleavage, then slightly increase at blastula stage and decrease by 6-fold during gastrula, 
neurula and tailbud stages.  It is then undetectable in the following developing stages.
87
  
Further studies also determined that the subcellular location of MIER1α changes with breast 
cancer progression in ductal epithelial cells.  There is a dramatic shift of MIER1α from the 
nucleus to the cytoplasm during the progression of invasive carcinoma.
91
 Investigation of the 
expression pattern in human tissue revealed that the human MIER1α isoform is found in 
specific cell types for almost every reproductive and endocrine tissue except the thyroid gland, 
which suggests it has particular function in endocrine tissue.
92
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 The common internal region in MIER1 contains several domains used for its role in 
regulating transcription (shown in Figure 1.4).  These domains include an N-terminal acidic 
region that functions as a transcriptional activator.
87
  An ELM2 domain that has been shown 
to recruit HDAC1 and repress transcription.
93
  A SANT domain shown to interact with the 
promoter specific transcription factor (Sp1) to interfering with transcription.
94
  The possible 
histone binding region in MIER1 has been shown to bind to H3K27ac. (Paterno et al, 
unpublished)  In addition, MIER1 has been shown to bind CBP in its N-terminal domain (the 
histone binding region as well as acidic and ELM2 domains) and inhibit its HAT activity.
95
  
MIER1 has been shown to interact with HMT G9a 
96
, and its role with this chromatin 
modifying enzyme has yet to be determined. 
 
1.2.2 MIER1 Structure  
 A number of studies have been conducted to characterise the structure and function of 
MIER1.  The mier1 gene encodes for six different protein isoforms with the same common 
internal region, through exon skipping, a facultative intron, three different polyadenylation 
signals, and two alternate promoters (P1 and P2).
90
  In humans there are three different N- and 
two different C- termini.  The different N-terminal isoforms (named N1, N2 and N3 in 
GenBank) result from the use of the two different promoters and alternative splicing.  Use of 
the P1 promoter can produce the exon 3A with the inclusion of the cassette and transcribes the 
isoform N1.  Inclusion of 3A encodes for an additional sequence containing a bona fide 
nuclear export signal (NES).
97
  The P1 promoter also encodes for N2 isoform and the use of 
P2 promoter encodes the N3 isoform.  The N2 and N3 isoforms (named N2 and N3 in 
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GenBank) have different start sequences, (ML in N2 and MAE in N3) but encode the same 
protein sequence after the start sequence.
97
 
 The two C-terminal isoforms known as MIER1α and MIER1β are created by the use of a 
facultative intron.  The α isoform results from the removal of the facultative intron and 
encodes a much smaller protein with the C-terminus consisting of 23 amino acids.  MIER1 α 
contains a LXXLL motif which is important in the interaction with nuclear hormone 
receptors.
90
  MIER1α has been shown to interact with estrogen receptor (ERα) in MCF7 cells 
and MIER1α over expression has been shown to inhibit estrogen-stimulated anchorage-
independent growth. 
91
  MIER1α is found in the cytoplasm because it does not have an NLS 
but it can be shuttled into the nucleus via interaction with nuclear proteins HDAC1/2.
98
  The β 
isoform results from the inclusion of the facultative intron and encodes a much larger protein 
with 102 amino acids in the C-terminus.  The β isoform has a NLS and is more widely 
expressed than MIER1α.90  There are two different distinct amino acid sequences for MIER1α 
and MIER1 β isoforms, which suggests that they both have distinctly different functions. For 
my experiments, I will be using the MIER1β isoform since it is the more commonly expressed 
isoform. 
 Studies of MIER1, and its different isoforms have shown it shares similar domains to other 
known epigenetic regulators, such as the: acidic region, a possible histone binding region, 
ELM2 domain, and the SANT domain,
87
 as shown in Figure 1.4.  Thus, MIER1 recruits 
chromatin modifiers through its conserved domains and transcription factors to suppress 
transcriptional activity.  The acidic region has an activation domain (amino acids 1-175) 
containing four stretches of acidic amino acids at the N-terminus that have been shown to 
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activate transcription.
87
  This function is often found in proteins that bind transcription 
factors.
99,100
  The histone binding region has been shown to bind H3K27ac and has been 
narrowed to amino acids 1-83 at the N-terminus (Paterno et al., unpublished data).  Currently 
it is known that the transcriptional activation function occurs in amino acids 1-109, and the 
histone binding region in amino acids 1-83.  Neither has been characterized to the smallest 
possible region, which is why they overlap. 
 The SANT domain, named for the transcription factors : SW13, ADA2, N-CoR and 
TF1113 (giving the acronym SANT) was originally found based on its homology to the DNA 
binding domain c-myb.
101
  The SANT domain was discovered as a small motif around 50 
amino acids in length, and is present in many nuclear receptor co-repressors.
102
  Proteins that 
contain one or more SANT domains are often involved in protein-protein interactions.  The 
SANT domain has been shown to interact with complexes that contain HMTs
75
,  HATs
103
 and 
HDACs.
104,105
   SANT domains are found in proteins regulating development including:  Egl-
27 and CoREST
106
, N-CoR
101
 and SMRT
102
.  SANT domains have also been shown to be a 
part of the chromatin remodelling complexes MTA-1 and MTA-2.
45,75
   
 The ELM2 domain (EGL-27 and MTA homology 2) was first identified in Egl-27, a 
Caenorhabditis elegans protein and encodes a protein similar to MTA1.
107
  This similar 
protein is a component of a complex with ATP-dependent nucleosome remodelling, and 
histone deacetylation activities.  It is also involved in protein complexes that are known to 
regulate the activity of transcription factors involved in embryonic patterning.
107
  The ELM2 
domain is evolutionarily conserved.  MIER1 contains both an ELM2 domain and a SANT 
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domain.  There are 13 known human co-repressor complexes that contain both domains.
31
  
This implies a structural, and/or functional relationship between the domains. 
1.2.3   MIER1 as an Epigenetic Regulator 
MIER1 acts as an epigenetic regulator enforcing transcriptional repression through two 
distinct mechanisms. The first mechanism is the interaction with transcription factors estrogen 
receptor α (ER) and Sp1.  The MIER1α isoform has been shown to interact with estrogen 
receptor α (ER).  Over expression of MIER1α dramatically decreases estrogen-stimulated 
growth of breast carcinoma cells illustrating that MIER1α functions as an ER co-repressor.91  
The SANT domain has been found to interact with Sp1.  This interaction causes the removal 
of Sp1 from the promoter of the target genes, including repressing transcription of MIER1’s 
own promoter which interferes with transcription.
94
 
The second mechanism is the recruitment/regulation of chromatin modifying enzymes 
through its N-terminal region, and conserved domains ELM2 and SANT.  MIER1 has been 
shown to bind the CREB binding protein (CBP) through its N-terminal region, including the 
histone binding and ELM2 domains.  CBP contains a BRD, and is a well-known HAT.  
However, interaction with MIER1 inhibits its HAT activity.
95
  The ELM2 domain of MIER1 
has been shown to recruit HDAC1, and repress transcription.
93
  In recent studies MIER1 has 
been shown to increase HDAC activity to H3K27ac, and remove the acetyl group. (Paterno et 
al., unpublished)  MIER1 has also been shown to interact with HMT G9a through its SANT 
domain, although MIER1’s exact function with the chromatin modifier G9a is 
unknown
96
(Paterno et al., unpublished data).   
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Given the information that MIER1 recruits the above modifying enzymes it is most likely 
that MIER1 works within a complex of these enzymes to repress transcription from H3K27 
target genes.  The methylation of H3K27 indicates repressed transcription, so the active 
transcription modification of acetylation must be removed from the lysine to begin repression. 
HDAC could be working in complex with MIER1 to remove the acetyl group from K27.  Also 
with MIER1 blocking the acetylase activity of CBP the lysine cannot be re-acetylated.  It has 
been shown that in Drosophila CBP specifically acetylates H3K27ac over other HATs.
74
  
Therefore it would be interesting to study if other HATs in humans would come to acetyl K27 
or not.  However in order for this process to occur MIER1 must read that there is an acetyl 
group on K27.  As mentioned previously, reader effector motifs are often found in complexes 
controlling gene repression.  Since MIER1 does not contain any recognizable reader domains 
(such as bromo-, chromo-, PHD or MBT), it likely uses a similar mechanism as other readers 
domain to recognize the acetyl modification and then recruit and bind the other modifiers 
CBP, HDAC, and G9a.  
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Figure 1.4: Domain Structure of MIER1 
P1 and P2 give rise to different MIER1 transcripts through different promoter use.  
Transcription from the P1 promoter produces either a start site of ML- or 
MFMFNWFTDCLWTLFLSNYQ- , the sequence encoded by exon 3A.  Transcription from 
the P2 promoter produces an isoform with a start site that begins with MAE-.  Through 
different use of the facultative intron 16 at the C-terminus creates two isoform MIER1α and 
MIER1β.  MIER1β results from the inclusion of the facultative intron.   The β isoform 
contains a nuclear localization signal (NLS).  The MIER1α isoform is produced when the 
intron is not included and results in a smaller protein.  The α isoform contains a classic 
LXXLL motif that is used for interaction with nuclear receptors.  All of the MIER1 isoforms 
share the same central domains including the acidic domain, histone interaction domain, 
SANT domain, and the ELM2 domain, as depicted above. 
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1.3 Purpose of this Study and Objectives 
 MIER1 has been found to interact, and recruit chromatin modifiers, and mostly likely 
work within a complex to repress transcription.  In recent data from a histone peptide array 
and peptide pull down arrays, MIER1 has been shown to only interact when H3K27 is 
acetylated from among many different single or combinations of modifications (acetylated, 
methylation, phosphorylation, citrullination, and unmodified) on the four core histones H2A, 
H2B, H3 and H4.  MIER1 is known to interact with HDAC, and in recent evidence, MIER1 
has been shown to increase HDAC activity towards the H3K27ac.  It then removes the acetyl 
modification from lysine 27, and this represses transcription. (Paterno et al., unpublished data)  
Recent data has demonstrated through the use of a deletion construct of MIER1, that the 
binding site of H3K27ac is in the first 83 amino acids in MIER1 (Paterno et al., unpublished 
data).  Given the above information, the purpose of this study was to determine the 
crucial binding sequence in MIER1 of H3K27ac.  We hypothesized that the binding site 
is in a conserved sequence that has been maintained through evolution, and is essential 
for the interaction of MIER1 on acetylated lysine 27 to repress transcription.   
Objective 1: Identification of Null-Binding H3K27ac full Length Mutant MIER1.  
Three conserved hydrophobic aromatic amino acids were mutated to all alanines.  A Not1 
restriction site was also introduced at the mutation site, for easy verification of the mutation. 
The mutant DNA was then purified.  The plasmid DNA was sent away for sequencing.  Full 
length mutant MIER1 would later be tested to see if it would still bind to acetylated H3K27 or 
not.  This would determine if the chosen amino acids were the binding location in MIER1 for 
H3K27ac.  
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Objective 2: Create a series of deletion constructs from amino acids 1-83 of MIER1. 
Creation of several different deletion constructs from the first 83 amino acids in MIER1 were 
completed to be tested if they would still bind to acetylated H3K27 and to narrow down the 
area of amino acids required for binding. 
Objective 3: Determination of a possible binding site in MIER1 for H3K27ac. 
A number of peptide pull down assays were performed with all of the full length mutant 
MIER1 proteins, deletion construct proteins, and wild type MIER1 to determine the binding 
ability of the MIER1 proteins to acetylated H3K27 and possible binding site. 
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Chapter 2- Materials and Methods 
 
2. Materials and Methods 
 
2.1 Plasmids and Constructs 
 
A. GST-hMIER1 β 
  hMIER1β – (accession number AY124191.1) GST-himer1 β fusion constructs were 
produced by Zhihu Ding (Terry Fox Lab, Division BioMedical Science, Faculty of Medicine, 
Memorial) B, PCR amplified products were cloned into TOPO PCR2.1 vector and digested 
with EcoR1, then inserted into the EcoR1 sites in the pGEX 4T.1 (GE Health Care).  This 
plasmid contains a GST-tag for isolating GST-fusion protein in experiments.    
B. GST-hMIER1β  Deletion Constructs 
 Deletion constructs of MIER1β (amino acids 1-35, 1-50 and 1-63) were PCR amplified 
(primers found in Table 2.4) from pcDNA3-MIER1β, cloned into TOPO PCR2.1 vector then 
digested with EcoR1 and ligated into pGEX 4T.1 at the EcoR1 site. Deletion construct amino 
acids 1-179 was PCR amplified using primers her34k and mi-her1 T100 (listed in Table 2.4 
pg 44) from CS3+MT-MIER1β, cloned into pCR3.1,  then digested with EcoR1 and ligated 
into pGEX 4T.1 at the EcoR1 site by Tina Blackmore (Terry Fox Lab, Division BioMedical 
Science, Faculty of Medicine, Memorial).  This plasmid contains a GST-tag for isolating 
GST-fusion protein in experiments. 
C. pcDNA3-hMIER1β  
 This construct was used as a template to amplify MIER1 sequence by PCR for cloning 
deletion constructs.  MIER1β was cloned into this vector (Invitrogen) at EcoR1 site of 
pcDNA3 by Yuan Lew (Terry Fox Lab, Division BioMedical Science, Faculty of Medicine, 
Memorial).   
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2.2 Site-Directed Mutagenesis  
 
2.2.1 Thermal Cycling for Producing Full Length MIER1 Mutants 
 
 Site Directed Mutagenesis was performed using mutagenesis primers (found in Table 2.1) 
this process resulted in mutating three amino acids to three alanine amino acids, and creating a 
Not1 restriction site.(Figure 3.2 depicting amino acid mutation pg. 56) Primers for mutations 
were designed using the Agilent Technologies QuikChange Primer Design 
https://www.genomics.agilent.com/primerDesignProgram.jsp.  Site Directed Mutagenesis was 
performed using two complimentary oligonucleotides containing the desired mutation, flanked 
by unmodified nucleotide sequences using thermal cycling, as per the manufacturers protocol 
(QuikChange 
® 
Lightning Site-Directed Mutagenesis Kit, cat # 210518).  Briefly, mutant 
strand synthesis was created by mixing in a, thin walled PCR tube : 2.5 µl of 10× reaction 
buffer, 50 ng (10 ng/µl) of  mier1β plasmid (wild type), 125 ng (100ng/µl) of oligonucleotide 
forward primer, 125 ng (100ng/µl) of oligonucleotide reverse primer (specific primer 
sequences found in Table 2.1), 1 µl of dNTP mix, 1 µl of QuikSolution reagent and dH2O to a 
final volume of 50 μl.  Lastly, 1µl of QuikChange® Lightning Enzyme was added.  Thermal 
cycling conditions were set using the parameters from Stratagene for the QuikChange 
Lightning Site-Directed Mutagenesis Kit, found in Table 2.2. After thermal cycling, the 
parental DNA was digested using 1 µl of the Dpn1 enzyme with an incubation of 20 minutes 
at 37 ºC.  Dpn1 treated DNA was transformed in XL Blue Cells as follows: 50 µl of cells were 
aliquoted in to 1.7 ml eppendorf tube, and 3 µl of Dpn1 treated DNA was mixed gently with a 
pipette tip and left to incubate for 30 minutes on ice.  Cells were then heat shocked for 30 
seconds at 42 ºC and placed on ice for two minutes.  250 µl of pre-warmed Luria-Bertani 
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broth (LB) [10 g tryptone (Fisher, cat # BP1421-500), 5 g yeast (Fisher, cat # BP1422-500), 
10 g NaCl (Fisher, cat # S640-10), 1 L dH2O, autoclaved] was aseptically added to each 
transformation and left to shake at 250-300 revolutions per minute (rpm) at 37 ºC for one 
hour.  100 µl was spread on pre-warmed agar plates containing (50 µg/ml) ampicillin (Amp; 
Sigma, cat # A-9518) and left inverted overnight at 37 ºC to grow.  The next day, one colony 
was re-streaked on a new LB Amp plate to confirm mutant plasmid transformation, and left to 
grown inverted overnight at 37 ºC.  One colony was picked the next day then the DNA was 
purified, as follows:  single colonies were grown overnight with 5 mls of LB and 5 µl of Amp 
(50µl/mg), and left to shake overnight at 37 ºC, 250-300 rpm.  The following morning, cells 
were pelleted at 1232 xg for 15 to 20 minutes.  The pellet was re-suspended, and plasmid 
DNA was collected as per manufacturer’s protocol (Promega Wizard Plus SV Mini Preps 
DNA Purification System, cat # A1460).  Briefly, after the cells had been pelleted, the 
supernatant was drained off and the pellet re-suspended in 250 µl of re-suspension solution.  
To break open the cells; 250 µl of a lysis buffer was used the tube was inverted to mix, and 
then it was left to incubate at room temperature until the solution was clear.  Furthermore 10 
µl of an Alkaline Protease solution was added to inactivate endonucleases, and other proteins 
released during the lysis.  The protease was added to the tube, inverted to mix the sample and 
left at room temperature for five minutes.  After incubation, 350 µl of a neutralization solution 
was added, and the tube was inverted to mix and then centrifuged at 14,000 xg for 10 minutes.  
The cleared lysate was decanted to the spin columns, and centrifuged at 14,000xg for one 
minute, and flow through discarded.  The column was washed 2x with a wash solution first 
with750 µl and then 250 µl.  The spin columns were centrifuging at 14,000 xg for one-two 
minutes and flow through discarded.  50 µl of nuclease free water was added to the spin 
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column and allowed to sit for a few minutes. Then the plasmid DNA was eluted by 
centrifuging at 14,000 xg for one minute.  The eluted DNA was stored at -20°C.  The 
concentration (ng/µl) of the eluted DNA was determined by Nanodrop Spectrophotometer 
2000.  The machine was blanked with 2µl of nuclease free water and then 2 µl of plasmid 
DNA was measured. 
 
2.2.2 Restriction Digest to Verify Mutation Site 
 
Purified DNA of full length MIER1 mutants were treated with Not1 restriction enzyme (15 
U/µl; Invitrogen, cat # 15441-017) as a preliminary check to determine if the desired mutation 
was created.  5µl DNA (500 ng) was digested with  2-3x excess restriction enzyme, 4 µl 10x 
REact
® 
3 buffer (Invitrogen, cat# 16303-018) and dH2O up to 40 µl.  Samples were incubated 
in a 37 
o
C water bath for one hour.  5 µl from the digested DNA was mixed with 2 µl 6x 
loading buffer (Ficoll®-400 in dH20, Sigma cat #F4375) and 5 µl of dH20, then loaded to a 
1% agarose gel. The samples were run around 100V for 45 minutes to confirm appropriate 
size of digestion.  Agarose gels were prepared by melting UltraPure™ agarose (Invitrogen, cat 
# 16500-500) in 1X TBE Buffer [Tris (Fisher, cat # BP152-1)/Borate (Fisher, cat # BP168-
500) /EDTA (Fisher, BP120-500)].  SYBR® Safe DNA gel stain(1 in 10,000 dilution) 
(Invitrogen, cat # S33102) was added to slightly cooled melted agarose in 1X TBE before 
liquid was poured into gel casting, and left to solidify at room temperature for about 30 
minutes.  Electrophoresis was carried out in 1X TBE. 
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Table 2.1: PCR primer pairs used for preparing MIER1 Full Length Mutants 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Full 
Length 
Mutant 
Forward Primer Reverse Primer 
YGY 5’GGC GAC ATG CCA ATT CAT GAA CTT 
CTC AGC CTT GCG GCC GCT GGT AGT 
ACT GTT CGA CTA CCT GAA GAA G 3’ 
5’ CTT CTT CAG GTA GTC GAA CAG TAC 
TAC CAG CGG CCG CAA GGC TGA GAA 
GTT CAT GAA TTG GCA TGT CGC C 3’ 
FDP 5’ GGT TCA GCA ACA TCA GAT GAC 
CAT GAA GCG GCC GCA TCA GCT GAC 
ATG CTG GTT CAT GAT T 3’ 
5’AAT CAT GAA CCA GCA TGT CAG CTG 
ATG CGG CCG CTT CAT GGT CAT CTG ATG 
TTG CTG AAC C 3’ 
MPI 5’ GAA ATA GAA GAT CTT GCA AGG 
GAA GGC GAC GCG GCC GCT CAT GAA 
CTT CTC AGC CTT TAT GGT TAT GG 3’ 
5’CCA TAA CCA TAA AGG CTG AGA AGT 
TCA TGA GCG GCC GCG TCG CCT TCC CTT 
GCA AGA TCT TCT ATT TC 3’ 
TLE 5’ GCT GAC ATG CTG GTT CAT GAT TTT 
GAT GAT GAA CGA GCG GCC GCA GAG 
GAA GAA ATG ATG GAA GGA GAA 3’ 
5’ TTC TCC TTC CAT CAT TTC TTC CTC 
TGC GGC CGC TCG TTC ATC ATC AAA ATC 
ATG AAC CAG CAT GTC AGC 3’ 
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Table 2.2: Thermal Cycling Conditions for Full Length MIER1 Mutant Synthesis 
Segment Cycles Temperature Time 
1 1 95 °C 2 minutes 
2 18 95 °C 20 seconds 
60 °C 10 seconds 
68 °C 30 seconds/kb of 
plasmid length =30 
sec*FL β 1500 bp+ 
4900 bp pGEX=195 
secs=3.20 mins 
3 1 68 °C 5 minutes 
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2.3 Cloning of Deletion Constructs 
 
 
2.3.1 Amplification of Deletion Constructs 
 
 
 Deletion constructs were amplified from MIER1β (wild type) pcDNA3 using Platinum® 
Taq  HiFi DNA Polymerase High Fidelity (5 U/µl; Invitrogen, cat # 11304-011).  PCR was 
performed in thin walled PCR tubes in an Eppendorf Mastercycler Gradient Thermocycler 
(specific conditions found in Table 2.3 pg 43).  Each reaction contained: 10 µl of pcDNA3 (10 
ng), 5 µl 10X High Fidelity PCR buffer (Invitrogen, P/N 52045), 2 µl 50mM MgSO4 
(Invitrogen P/N 52044), 1 µl 10mM dNTPs(2.5 mM of each dNTP), 100ng/µl her47 (forward 
primer), 100 ng/µl reverse primer (specific sequence found in Table 2.4, found on pg 44) , 0.2 
µl Platinum
®
 Taq DNA High Fidelity( Invitrogen, cat# 11304-011), and dH2O up to 50 µl. 
 After amplification samples were put on ice, additional 3’ A-overhangs were added to the 
reactions by mixing with the pipette tip 1 unit of Taq polymerase (5U/µl; Invitrogen, cat # 
18038-042).  The tube was then incubated at 72 ºC for 10 minutes without cycling.  The tube 
was then immediately put on ice and used in the TOPO® cloning reaction. 
 
2.3.2 TOPO Cloning 
 
 
 The amplified adenylated PCR product was cloned into pCR™ 2.1- TOPO ® vector as per 
manufacturers protocol (TOPO ®TA® Cloning Kit Invitrogen, cat # 45-0641).  Briefly, 4 µl 
of PCR product was mixed with, 1µl of salt solution (1.2 M NaCl and 0.06 M MgCl2), and 1 
µl of TOPO® vector.  It was allowed to incubate at room temperature for five minutes.  2 µl 
of TOPO® cloned reaction was transformed into 50 µl XL Blue cells, as in section 2.2.1.  
Colony PCR was performed as in section 2.3.3, on multiple colonies to check for inserts.  
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Positive colonies that contained the appropriate insert were purified by bacterial mini-prep, as 
follows: single colonies were grown overnight with five mls of LB and 5 µl of Amp 
(50µg/ml), and left to shake overnight 37 ºC at 250-300 rpm.  The following morning cells 
were pelleted at 1232 xg for 15 to 20 minutes. The pellets were re-suspended and plasmid 
DNA collected as per manufacturers protocol (Promega Wizard Plus SV Mini Preps DNA 
Purification System, cat # A1460) as described in section 2.2.1.  The concentration (ng/µl) of 
the eluted DNA was determined by Nanodrop Spectrophotometer 2000.  The machine was 
blanked with 2 µl of nuclease free water and then 2 µl of plasmid DNA was measured.  The 
TOPO® cloned deletion constructs were sent for sequencing to TCAG DNA Sequencing 
Facility (Toronto, Canada) to confirm proper sequence orientation, as described in section 
2.4.5 
 
2.3.3 Colony PCR 
 
 
Following bacterial transformation as in section 2.2.1, individual colonies were picked up 
with a sterile disposable pipette tip and re-suspended in a master mix.  PCR was performed in 
thin walled PCR tubes in an Eppendorf  Mastercycler Gradient Thermocycler conditions are 
found in Table 2.5.  Each reaction contained 1 µl of template DNA (re-suspended colony as 
the template DNA) with master mix made containing: 5 µl 10X PCR buffer (Invitrogen, P/N 
Y02028) , 1.5 µl 50mM MgCl2 (Invitrogen P/N Y02016), 4 µl 10mM dNTPs(2.5mM of each 
dNTP), 2 µl of 100µg/ml pCRSP/2.1 and pCRT/2.1 respectively (specific primer sequences 
for different vectors found in Table 2.6 pg 46), 0.2µl Taq DNA polymerase, and dH2O up to 
50 µl.  The pipette tip from each colony after re-suspension in the master mix was then 
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scratched on a LB Amp plate (50 µg/ml) and left to grow overnight at 37ºC.  The colonies 
were checked again in the same manner to confirm the insert or ligation reaction.  Positive 
colonies were purified as in section 2.2.1.  PCR products were visualized by agarose gel 
electrophoresis, by mixing 10 µl of the PCR products with 2 µl of 6x DNA loading dye, 
loaded and run on a 1.2% agarose gel for 25 minutes around 115V, to confirm appropriate size 
of insert.  Agarose gels were made by melting UltraPure™ agarose with 1X TBE Buffer (Tris 
/Borate/EDTA).  SYBR® Safe DNA gel stain(1 in 10,000 dilution) was added to slightly 
cooled melted agarose, in 1X TBE before liquid was poured into gel casting, and left to 
solidify at room temperature for about 30 minutes.  Electrophoresis was carried out in 1X 
TBE.   
 
2.4 Sub-cloning 
 
2.4.1 Restriction Digest of Deletion Construct Inserts and Vector 
 
The purified TOPO® cloned deletion construct inserts vector (pGEX 4T.1; from section 
2.3.2) were both digested with EcoR1 (15U/µl) (Invitrogen, cat # 152-02013).  The vector and 
inserts 5µl (500ng), respectively were digested with 2-3x excess appropriate restriction 
enzyme, 4µl 10X buffer H (Invitrogen, cat # A1501A), and mixed with dH2O up to 40µl.  
Samples were incubated in a 37 
o
C water bath for 1 hour.  5 µl of the digested DNA was 
mixed with 2 µl of 6x loading buffer and 5 µl of dH20, then loaded to a 1.2% agarose gel to 
confirm digestion of inserts and vector had occurred.  Agarose gels were made by melting 
UltraPure™ agarose in 1X TBE Buffer (Tris/Borate/EDTA).  SYBR® Safe DNA gel stain (1 
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in 10,000 dilution) was added to slightly cooled melted agarose in 1X TBE before liquid was 
poured into gel casting, and left to solidify at room temperature for about 30 minutes.  
Electrophoresis was carried out in 1XTBE.   
 
2.4.2 Alkaline Phosphatase Treatment of DNA 
 
 
The digested vector DNA was treated with Calf Intestinal Alkaline Phosphastase (CIAP; 20 
U/µl; Invitrogen, cat # 18009-019) to remove the 5’-phosphate groups, in order prevent re-
circularization and re-ligation of the vector.  Up to 10 pmol of digested DNA was used with 
0.01U/µl CIAP/pmol of ends in CIAP buffer. Samples were incubated in a 37 
o
C water bath 
for 30 minutes.  Another aliquot of the same amount of CIAP used before was added, and left 
to incubate at 37 
o
C for another 30 minutes.  CIAP treated DNA was then mixed with 6x DNA 
loading dye and loaded to a 1.2% agarose gel for gel purification.  Agarose gels were made by 
melting UltraPure™ agarose in 1X TBE Buffer (Tris/Borate/EDTA).  SYBR® Safe DNA gel 
stain (1 in 10000 dilution) was added to slightly cooled melted agarose in 1X TBE, before 
liquid was poured into gel casting, and left to solidify at room temperature for about 30 
minutes.  Electrophoresis was carried out in 1XTBE.   
 
2.4.3 Agarose Gel Purification 
 
 
Agarose gels were visualized with UV light, and the appropriate sized DNA fragment was 
cut from the gel using a disposable razor blade.  The gel slice was then placed in a pre-
weighted 1.7 microcentrifuge tube.  Purification of DNA from gel pieces was performed as 
per manufactures protocol using the Qiagen QIAquick Gel Extraction Kit, using all the kits 
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reagents (Qiagen, cat # 28704).  Briefly, 3 volumes of Buffer QG to 1 volume of gel were 
added to the gel slice and left to incubate at 50 °C for 10 minutes.  After the gel slice was 
dissolved completely, the color of the mixture was checked for the same yellow color of 
Buffer QG. If the mixture was not the appropriate yellow color 10 μl of 3M sodium acetate 
was added to readjust the pH to pH≤7.5. 1 gel volume of isopropanol (Sigma, cat # I9516) 
was added to the sample, mixed and then transferred to a QIAquick spin column, in a 
provided 2 ml collection tube.  The spin column was centrifuge at 10,000xg for one minute 
and flow-through was discarded.  Next, 500 µl of Buffer QG was added to the QIAquick 
column, then centrifuge for one minute at 10,000 xg.  To wash the column, 750 µl of Buffer 
PE was added to QIAquick column, and centrifuge for one minute at 10,000xg, the flow-
through was discarded and the QIAquick column was centrifuged again for one minute at 
10,000 xg.  The QIAquick column was put into a clean 1.7 ml microcentrifuge tube and DNA 
was eluted with 30 μl of dH2O.  The dH2O was allowed to sit on the column for around one 
minute, and then centrifuged for one minute at 10,000xg.  From the extracted DNA 2 µl was 
mixed with 10 µl of 6 x loading buffer and run on a 1.2 % agarose gel to confirm the extracted 
DNA was the right size.  An agarose gel was made by melting UltraPure™ agarose with 1X 
TBE Buffer.  SYBR® Safe DNA gel stain (1 in 10,000 dilution) was added to slightly cooled 
melted agarose, in 1X TBE before the liquid was poured into the gel casting, and left to 
solidify at room temperature for about 30 minutes.  Electrophoresis was carried out in 1X 
TBE with a voltage around 120V for 20 minutes. 
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2.4.4 Ligation 
 
A 20 µl ligation reaction was prepared using 1:3 molar ratio of vector: insert gel purified 
samples from section 2.4.3.  The concentrations needed for the inserts were calculated using 
the following formula basing the vector concentration on the band intensity similarity to the 
1000 bp marker in the 1 kb plus DNA ladder. 
                                                                     
(roughly 11.5 ng of construct aa 1-63, 9.1 ng of construct aa 1-50, 6.4 ng of construct aa 1-35, 
3.5 ng of construct aa 1-19, and 100 ng of vector) mixed with 5x ligase reaction buffer 
(Invitrogen, cat P/N Y90001), 1µl of T4 DNA ligase (5U/µl) (Invitrogen, cat # 15224-041), 
0.5 µl of 10 mM dATP (Promega, E601D) and dH2O to 20 µl.  The reaction was gently mixed 
with a pipette tip, and left to incubate at room temperature for two hours.  2 µl from each 
ligation reaction was transformed as in section 2.2.1 in 50 µl of XL Blue cells.  Colonies were 
PCR checked (as in section 2.3.3) for ligated insert in the pGEX 4T.1 vector with appropriate 
vector primer (found in Table 2.6, pg 46).  One colony was re-streaked on a new LB Amp 
plate to confirm ligated insert and left to grown inverted overnight at 37 ºC.  Positive colonies 
that contained the appropriate ligated insert were purified by bacterial mini-prep, as follows:  
single colonies were grown overnight with 5 mls of LB, 5µl of Amp (50µg/ml), and left to 
shake overnight 37 ºC at 250-300 rpm.  The following morning cells were pelleted at 1232 xg 
rpm for 15 to 20 minutes.  The pellets were re-suspended and plasmid DNA collected as per 
manufacturers protocol (Promega Wizard Plus SV Mini Preps DNA Purification System, cat # 
A1460) as described in section 2.2.1.  The concentration (ng/µl) of the eluted DNA was 
determined by Nanodrop Spectrophotometer 2000.  The machine was blanked with 2 µl of 
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nuclease free water and then 2 µl of plasmid DNA was measured.  The deletion constructs 
were sent for sequencing to confirm proper sequence orientation, as described in section 2.4.5. 
 
2.4.5 Sequencing Analysis  
 
 
 The full length mutants and deletion constructs correct sequences were confirmed by the 
TCAG DNA Sequencing Facility (Toronto, Canada).  The samples were sent to be processed, 
in the required concentrations by the facility of 200-300 ng in 7.0 µl of purified template 
DNA.   Also included was 50 ng in 0.7 µl of primers for each forward and reverse sequencing 
reaction, in two separate tubes for a total volume of 7.7 µl in each tube. 
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Table 2.3: PCR Thermal cycling conditions for creating MIER1 Deletion Constructs 
 
Cycles Temperature Time 
1  94 °C 2 minutes 
30 94 °C 30 seconds 
55 °C 30 seconds 
68 °C 30 seconds 
1 68 °C 5 minutes 
1 30 °C 1 second 
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Table 2.4: PCR primer pairs used for preparing MIER1 Deletion Constructs 
 
Deletion Construct Forward Primer *  Reverse Primer** 
aa 1-179 5’ CAC CAT GGC GGA GCC ATC TGT 
TGA ATC 3’ 
5’ GCC CTA CCA GTC TTC TGA TGG 
AAT 3’  
aa 1-63 5’ CAC CAT GGC GAC ATC TGT TGA 
ATC 3’ 
 5’ CG GAA TTC CTA GTC GCC TTC 
CCT TGC AAG 3’ 
aa 1-50 5’ CAC CAT GGC GAC ATC TGT TGA 
ATC 3’ 
5’ CG GAA TTC CTA GTT TGT TTC 
TCC TTC CAT CAT 3’ 
aa 1-35 5’ CAC CAT GGC GAC ATC TGT TGA 
ATC 3’ 
5’ CG GAA TTC CTA ATC AAA ATC 
ATG AAC CAG 3’ 
aa 1-19 5’ CAC CAT GGC GAC ATC TGT TGA 
ATC 3’ 
5’ CG GAA TTC CTA ATC GTC TGA 
TGT TGC TGA 3’ 
Primers for deletions constructs were checked with IDT Oliogo Analyzer for the correct Tm, 
GC% content (around 40%), hairpin structures and self- dimer.   
*(her 47 for all except 1-179) (her 34K for 1-179) 
**(mi-her1 T-100 for 1-179) 
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Table 2.5: PCR Thermal cycling conditions for checking Deletion Constructs inserts 
Cycles Temperature Time 
1  94 °C 5 minutes 
30 60 °C 1 minute 
72 °C 1 minute 
94 °C 1minute 
1 60 °C 1 minute 
1 72 °C 7 minutes 
1 30 °C 1 second 
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Table 2.6: PCR primer pairs used for checking for inserts 
 
Primer Forward Primer Reverse Primer 
pCRSp/2.1 5’ GCT CAC TCA TTA GGC ACC C 3’   
pCRT/2.1  5’ GGC GAT TAA GTT GGG 
TAA CG 3’ 
pGEX 1.1 5’ GGG CTG GCA AGC CAC GTT TGG T 
3’ 
 
pGEX 1.2  5’ CCG GGA GCT GCA TGT 
GTC AGA GG  3’ 
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2.5 Peptide Pull Down Assay with GST-fusion Proteins 
 
 
2.5.1 GST-fusion protein production 
 
 GST fusion plasmids were transformed into competent Rosetta Cells™ (Millipore, cat 
#70953-4).  First 100 µl of competent cells were aliquoited to 1.7 ml eppendorf tube, and 10 
ng of purified DNA was mixed gently with a pipette tip, and left to incubate for 30 minutes on 
ice.  Cells were then heat shocked for 45 seconds at 42 ºC, and placed on ice for two minutes.  
500 µl of pre-warmed LB was aseptically added to each transformation, and left to shake at 
250-300 rpm at 37 ºC for one hour.  100 µl was spread on pre-warmed agar plates containing 
(50 µg/ml) ampicillin, and plates were left inverted overnight at 37º.  The next day, one 
colony was re-streaked on a new LB Amp plate to confirm mutant plasmid transformation, 
and left to grown inverted overnight at 37ºC.  The following day, single colonies were grown 
overnight with 5 mls of LB plus ampicillin (50µg/ml).  The morning of the third day 1 ml was 
added to 250ml of LB and Amp (50 µg/ml), and left shaking at 37 ºC to grow to an OD600 of 
0.80-1.0.  To check optical density, 1 ml of LB medium was added to a cuvette, and used as a 
blank to calibrate the machine 1 ml of inoculated culture was added to another cuvette and the 
measurement taken.  OD was read on a spectrophotometer at a wavelength of 595.  Once the 
culture reached the desired OD it was then induced with 25 µl of 1M IPTG (isopropyl- β-D- 
thiogalactopyranoside; Fisher cat #BP1755-1), and left shaking overnight at room 
temperature.  In the morning cells were pelleted at 3000 rpm for 10 minutes at 4 ºC in 250 ml 
Nalgene polypropylene bottles.  The liquid was drained off and the pellet frozen until it was 
solid.  The pellet was thawed at room temperature, and re- suspended in 5 mls of ice-cold 1X 
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PBS (phosphate buffered saline; Sigma, cat # P3813).  The re-suspended pellet was 
transferred to a new sterile 50 ml falcon tube and 50 µl of 0.2 M PMSF (phenylmethylsulfonyl 
fluoride; Sigma, cat # P7626) was added.  The cells were then lysed by sonication (70% 
amplitude, 2 x 15 second pulses with 30 second break in-between).  Next, 500 µl of 10% NP-
40 (Nonidet P40’; Sigma, cat # 74385) was added, and samples were left on ice for 20 
minutes.  The tubes were then centrifuged at 10,000 x g for 15 minutes.  The soluble faction 
was removed, and stored in 1 ml amounts in labelled 1.7 ml eppendorf tubes at -70 ºC.  SDS-
PAGE (sodium dodecyl sulfate – polyacrylamide gel electrophoresis) was used to determine 
the concentration and purity of GST-Fusion proteins.  
2.5.2 Isolation and detection of GST-fused proteins 
 
 
Glutathione Hi-Cap Matrix beads (Qiagen, cat# 30900) were aliquoited into 1.7 ml 
eppendorf tubes and washed by adding 1 ml of GST-Pull Down Buffer [20mM Tris HCL 
pH7.5, 150mM NaCl, 0.1% NP40 in PBS, 10% Glycerol (Fisher, cat #56-81-5; added right 
before use), dH20], inverting until the beads were suspended in the buffer, then allowing 
rotation for one minute at room temperature.  The beads were centrifuged at 5000 x g for 30 
seconds and the supernatant was aspirated off by vacuum. This was repeated two more times.  
Then the beads were re-suspended in a 50% slurry with GST- Pull Down Buffer.  50 µl of the 
50% slurry of Glutathione Hi-Cap Matrix beads were aliquoted into new 1.7 ml tubes.  The 
beads were washed twice with 1 ml of 1 x PBS in the same manner as with GST Pull-Down 
Buffer.  After washing, varying amounts of soluble GST-fusion protein (25 µl, 50 µl, 100µl 
and 200 µl) and enough GST Pull Down Buffer to equal 1 ml + 5 µl of 0.2 M PMSF was 
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added to the sample and rotated at 4
 o
C for 1 hour.  After incubation, the beads were washed 
with 1 ml 2x with GST Pull Down Buffer with 2% NP-40 solution added to wash away 
unbound proteins.  A final wash with 1 ml of 150mM NaCl was done using the same method 
as above.  To the washed beads, 30 µl of 2 x SSB (Sodium dodecyl sulfate [SDS] Sample 
Buffer (Sigma, cat # L5750) + Bromophenol blue dye [BDH Chemicals, cat # 44305]) was 
added and the samples were vortexed lightly then boiled for four minutes to denature the 
proteins.  The samples were allowed to cool on ice for three minutes, before lightly vortexing, 
then centrifugation at 5000 x g for one minute to bring the beads to the bottom of the tube.  
The supernatants were then run on a 7% [for full length MIER1(wild type) and mutant full 
length MIER1] or 10% SDS-PAGE gel (deletion constructs) and stained with Coomassie Blue 
Stain (Biorad, cat # 161-0400) for one hour shaking at room temperature.  The gel was then 
de-stained overnight in 1 L of destain (740ml dH2O, 200 ml methanol [ACP, cat# M-3640], 
and 60 ml glacial acetic acid [ACP, cat # A-0302]) and dried under vacuum for one hour. 
 
2.5.3 Peptide Pull Down Assay 
 
 
 Glutathione Hi-Cap Matrix beads, 100 µl per sample were aliquoted in a 1.7 ml eppendorf 
tube and washed by adding 1 ml of GST-Pull Down Buffer [20 mM Tris HCL pH7.5, 150mM 
NaCl, 0.1 % NP40 in PBS, 10 % Glycerol (added right before use), 1 mM DTT [DL-
Dithiothreitol (added right before use; Sigma, cat # D5545-1)], dH2O], inverting until the 
beads were suspended in the buffer, and then allowing them to be gently vortexed.  The beads 
were then centrifuged at 5000 xg for 30 seconds.  This process was repeated two more times.  
Then the beads were re-suspended to a 50% slurry in GST- Pull Down Buffer and for each 
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pull down reaction, 100 µl of 50 % slurry was used.   Each sample reaction contained a total 
volume of 500 µl in a 1.7 ml eppendorf tube: the GST protein (pre-determined amount), GST-
Pull Down Buffer and 2.5 µl of 0.2 M PMSF. To make up for the different volumes of 
proteins being used, any of the protein samples with less than the highest volume amount of 
protein being used per experiment had a 1 % NP-40 solution added so that the total volume 
equalled 500 µl.  The tubes were then rotated for one hour at 4ºC.  After an hour the tubes 
were centrifuged at 5000 xg for 30 seconds.  The supernatant was aspirated off and the beads 
were washed 4x in the same manner as above. The beads were then washed with 1 ml of 150 
mM NaCl as per GST-Pull Down Buffer.  Then, 100 µl of Elution Buffer [10mM Glutathione 
(Sigma, cat # G4251), 100 mM Tris HCL pH8] was added to the beads, and allowed to rotate 
at half rotation for 20 minutes.  After 20 minutes the supernatant was removed and stored; 100 
µl more of Elution Buffer was added and allowed to rotate at half rotation for 20 minutes 
more, then added later.  Eluted protein was then run over buffer exchanged de-salting columns 
(Zeba
®
 Spin Desalting Columns 0.5 mls cat # 89883), as per manufacturer’s protocol using 
300 µl of interaction buffer [GST PD Buffer, 1mg/mL BSA cat # A7888 Sigma, 1mM PMSF].  
In a 1.7 ml eppendorf tube 150µl of Interaction Buffer, 40 µl of buffer exchanged protein and 
10µl of a 1/50 diluted, 1 mg/ml stock of Histone peptide (AnaSpec Histone Peptides, GK 
Biotin) H3 (21-44; cat# 64440-25) unmodified [only used for full length mutant TLE] and 
H3K27ac (21-43; cat # 64637-025) was mixed and left to incubate overnight at 4 ºC on half 
rotation.  An input sample was also prepared by mixing 2 µl of buffer exchanged protein, and 
28 µl of 1xSSB + Bromophenol blue dye and stored at -20ºC.  In the morning, 50 µl of a 50 % 
NeutraAvidin ® Agarose Resin (Thermo Scientific cat # 29200) beads were prepared in the 
same manner as Glutathione Hi-Cap Matrix beads, and added to each overnight reaction plus 
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200 µl of interaction buffer.  The tubes were allowed to rotate for one hour at 4ºC.  After 1 
hour, tubes were centrifuged at 5000 xg for 30 seconds, and the supernatant was aspirated off.  
The beads were then washed 4x with GST-Pull Down Buffer and then once with 150 mM 
NaCl as before.  The beads were re-suspended in 30 µl of 1.5 X SSB+ Bromophenol blue dye, 
boiled for four minutes, allowed to cool on ice, vortexed lightly and then centrifuged for 30 
sec at 5000 x g.  The supernatant loaded on a 7 % or 10 % SDS-polyacrylamide gel, 
depending on the size of the protein being tested.  The gels were transferred to a PVDF 
membrane with the Biorad Trans-Blot
®
 Turbo™ Transfer System at a voltage of 25 V, a 
constant current of 2.5 Amps, and 12 minutes for full length MIER1 mutants and 25 V, 
constant current of 2.5 Amps, and 10 minutes for deletion constructs.  The membranes were 
blocked in SuperBlock
® 
T20 (TBS) Blocking Buffer (ThermoScientific, cat #37356).  Western 
Blot analysis was performed with an Anti- GST (0.25 ug/ml, mouse monoclonal (GenScript, 
cat# A00865) antibody in SuperBlock
® 
for one hour, then washed 5 times in one hour, shaking 
at room temperature in 1 X TBS-T [20 mM Tris pH 7.6, 150 g NaCl, Tween 20 (Sigma, cat # 
P2287), dH2O].  Secondary Antibody 1:5000 dilution of sheep-anti mouse- horseradish 
peroxidase (HRP; GE Health Care UK Limited cat# NA931V) in SuperBlock
®
 was added, 
and was left to shake at room temperature for one hour.  The membrane was washed 5 times 
in 1hour again by shaking in 1 X TBST at room temperature and analyzed with 
chemiluminescent detection using ECL Clarity Western Blotting system and Hyperfilm HCL 
(BioRad, cat # 170-5061). 
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Chapter 3: Results 
 
3.1 Creating Full Length MIER1 Mutants  
 
3.1.1 Mutating Conserved Amino Acids within the first 83 Amino Acids of MIER1  
 
 In previous research pull down assays were performed in order to determine which region 
in MIER1 bound H3K27ac.  The amino acids 1-83 were determined to be the smallest region 
capable of binding to H3K27ac.   This was found using different size constructs of the MIER1 
protein, until binding was still observed to the H3K27ac peptide. (Paterno et al., unpublished 
data) 
The purpose of this project was to more precisely define which of the first 83 amino acids 
were required to specifically bind H3K27ac.  It has been demonstrated that the binding site of 
proteins to acetylated lysines, uses a bromodomain (BRD) with highly conserved hydrophobic 
and aromatic amino acids within a hydrophobic pocket.  One study found specific tyrosines 
and a valine were the essential amino acids, in the hydrophobic pocket formation required for 
binding to the acetylated lysine.
56
  These aromatic side chains form a hydrophobic core, and 
are involved in the stability, and formation of the secondary, and tertiary structure along with 
the function of the protein.
52,56,108,109
  However, MIER1 does not contain a BRD but might still 
use the same method of utilizing a hydrophobic pocket formed by aromatic side chains to bind 
H3K27ac.   
 The way in which reader domains bind to hydrophobic amino acids in acetylated histones 
was used to find a novel binding domain for acetylated lysines in the MIER1 protein.  
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Knowing that the sequence of amino acids 1-83 contained the binding site this area was 
examined for a possible hydrophobic pocket used for binding.  Since there is no available 3-D 
model of MIER1 it was not possible to determine if there is a hydrophobic pocket in the 
tertiary structure of the folded protein.  Since the amino acids used in BRDs to bind acetylated 
lysine residues are conserved amino acids, it was assumed that the amino acids H3K27ac is 
binding of MIER1 are likely conserved through different species.  It was also assumed that the 
amino acids used in binding are likely to be hydrophobic as well.  Also given that other 
binding sites have been identified within the conserved domains of MIER1 by mutating 
conserved amino acids, we used this knowledge in conjunction to determine the binding site.
93
   
   An alignment was used with the first 83 amino acids of MIER1 from fifteen different 
species to identify conserved amino acids in, human, rabbit, horse, elephant, dog, cat, whale, 
walrus, chicken, Xenopus, mouse, zebrafish, daphnia, Drosophila, and C.elegans.  Figure 3.1 
showed which amino acids in the sequence were conserved between the many species.  The 
alignment figure most importantly compared which hydrophobic, and aromatic amino acids 
were conserved between the different species. 
 The first set of experiments used site-directed mutagenesis to study the binding site since 
other researchers have used this method to mutate conserved amino acids to elicit a change in 
function of the protein, or determine a binding location.
56,74
  Sites were chosen to be mutated 
from the alignment in Figure 3.1, and these were the amino acids: [
73
YGY
75
 ], [
64
MPI
66
],    
[
22
FDP
24
].  The first full length mutant produced was the YGY to AAA.  Alanines are most 
commonly used for site directed mutagenesis, because they are small and aliphatic in nature 
which causes the biggest change in a binding conformation.  Glutamine has also been used as 
a substitution in site directed mutagenesis.
56,74,110
  A Not1 restriction site was introduced at 
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location of the mutagenesis in the wild type DNA sequence.  Each mutation consisted of three 
amino acids, which meant the sequence was long enough to change the wild type DNA 
sequence into the Not1site: GCGGCCGC.  The wild type codons were being mutated to all, 
alanines which can be expressed as: GCT, GCC, GCA or GCG.  Therefore, wild type codons 
were arranged to solely alanines, and in the process created the sequence to also be a Not1 
restriction site.  The introduction of the restriction site where the mutation was located was 
used to initially verify the mutagenesis, and it can also distinguish the mutated MIER1β 
protein from the wild type MIER1β protein.  If ever in the event there was ever mix of the two 
a restriction digest could be performed, and the mutated full length MIER1β should show two 
bands from the digest.  One from the cut at the mutation site, and the other at the multiple 
cloning site in the pGEX 4T.1 vector.  The wild type MIER1β should show only one band 
from a cut in the multiple cloning site of the pGEX 4T.1 vector.  A Not1 restriction site was 
introduced at the mutation site in all full length MIER1 mutants.  This can be seen in Figure 
3.2 which is a schematic of mutation change, and introduced restriction site.  Three other full 
length MIER1β mutants were created based on the same criteria as above where the 
hydrophobic amino acids, were mutated with aromatic side chains in order to identify the 
H3K27ac binding site.  The two other full length mutations were MPI-AAA, at amino acids 
64-66, and FDP-AAA at amino acids 22-24. All of the full length mutants were sent away for 
sequencing to confirm mutation, as described in section 2.4.5. 
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Figure 3.1: Conserved 1-83 amino acid Sequence of MIER1 in Various Species 
 Around the first 83 amino acids of MIER1 aligned in 15 different species to determine 
which amino acids were logical candidates for mutate, and locate the binding site of 
H3K27ac.  The highlighted blue amino acids are hydrophobic, and the highlighted brown 
amino acids are aromatic, or have aromatic side chains. The amino acids are in sequence 
starting at amino acid one as seen on the left hand side of the diagram in each species, and 
numbered progressively to around 83 amino acids (ranging from 81-86) as seen beside the 
species name on the right hand side of the diagram.  At the bottom of the diagram are colons 
indicating conservation between groups of strongly similar properties (scoring > 0.5 in the 
Gonnet PAM 250 matrix).  A period indicates groups of weakly similar properties (scoring =< 
0.5 in the Gonnet PAM 250 matrix).  An asterisk indicates a single conserved residue between 
the species. 
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Figure 3.2: MIER1 sequence showing mutation and restriction site 
 This diagram shows the wild type MIER1β amino acid sequence with 73Y, 74G, 75Y 
highlighted in green on the bottom. Above the mutated amino acid sequence of all alanines is 
highlighted in red.  The nucleotide sequence of the wild type and mutant sequences are in 
capital letters, and in the mutant sequence a Not1 restriction site can be seen. 
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3.1.2 Expression of Full Length MIER1 Mutants 
 
Restriction digests were performed with the full length MIER1β mutants, and wild type 
MIER1β plasmid DNA sequences to quickly determine if the mutagenesis created the 
mutations.  If the mutagenesis was successful, and the wild type sequence was altered to the 
sequence for Not1, then the digest would show two bands.  The first band would be the Not1 
restriction site in the pGEX 4T.1 vector, and the second band would be the size distance from 
the first restriction site to the second Not1 site in MIER1β at the mutation site.  There is a 
Not1 restriction site in the GST-vector near the multiple cloning sites of wild type MIER1β.  
This was used as a positive control, and shows up as a linearized plasmid band equal in size to 
the GST-vector plus MIER1β (approximately 6550bp). The digests were run on an agarose 
gel, and visualized under UV light to determine if there was an extra band in the full length 
mutant DNA from the restriction enzyme.   
The restriction digest showed that there was one band in the wild type MIER1β lane 
around, 6550bp which is the expected size of the GST pGEX 4T.1 vector (approximately 
5000bp), and MIER1β (approximately 1550 bp) combined.  In the full length mutant lane 
there, are two bands of the appropriate size fragment of the vector, and the mutation site in 
MIER1β demonstrating the desired mutation was created.  The first band in the full length 
mutant lane is from the restriction cut at Not1 site in the multiple cloning site of the GST-
vector resulting in, a linearized GST-vector, which is around 5000 bp.  The second band is 
from the Not1 restriction cut at the mutated site around 1550 bp.  The T38A, L39A, E40A 
mutant versus wild type digest, can be seen in Figure 3.3.  Restriction digests of the plasmid 
DNA from all full length mutants showed an extra band from the introduced mutation.  All 
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full length mutants were sent away for DNA sequencing to confirm that the wild type 
sequence was mutated sequence, as described in Section 2.4.5. 
The GST-fusions proteins (wild type MIER1β, full length MIER1β mutants and GST-
vector proteins) were prepared, purified and run on a SDS-PAGE gel with varying amounts of 
protein. This was followed by staining with Coomassie Blue, as in sections 2.5.1 and 2.5.2 at 
different time points whenever the protein was needed for an experiment.  However, since all 
of the GST-fusion proteins were not produced at the same time they therefore were not 
accurately measured for concentration, until compared on the same SDS-PAGE gel.   By 
running all of the proteins together allowed us to determine what amount for the GST-fusion 
proteins was needed to use for a consistent 1 µg of protein per sample.  To determine how 
much protein was needed in a 1 µg sample for each of the mutant, and wild type full length 
MIER1β proteins for use in future experiments a known volume with 1 µg of just GST protein 
was run alongside the full length wild type, and mutant MIER1β proteins for comparison. 
 Once the determined amounts for each full length MIER1β 1 mutant, wild type MIER1β, 
and GST proteins were decided a sample of each was then run on the same gel for 
comparison, and can be seen in Figure 3.4. 
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Figure 3.3: Restriction Digest of TLE Mutant 
 
 Restriction Digests were performed as described in the Material and Methods.  Wild type 
MIER1 and full length mutant MIER1 DNA was incubated with a Not1 restriction enzyme in 
a 37 °C water bath for one hour, then run on 1% agarose gel to separate DNA by appropriate 
size fragments and visualized under UV light.  A single band was expected in the full length 
wild type MIER1 lane representing linearized DNA from Not1 restriction site cut in the GST-
vector of about 6550bp.  This band can be seen in the second lane.  In the third lane which 
contains full length MIER1 mutant a band can be seen with a fragment cut, for the Not1 site in 
the GST vector around the expected 5000bp.  The expected second cut fragment is around 
1550 bp from the introduced Not1 restriction site and can be seen in the third lane with an 
arrow indicating the second fragment cut. 
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Figure 3.4: GST-Fusion Protein of Wild Type, Full Length Mutant MIER1β and GST 
 
 GST fusion proteins were prepared as described in Material and Methods.  Around 1µg of 
full length MIER1β GST-fusion proteins were purified through binding to Glutathione Hi-Cap 
Matrix beads (Qiagen, cat# 30900) and then eluted and run on a SDS-PAGE gel. The gel was 
stained with Coomassie Blue and dried down.  The top arrow indicates the full length mutants 
and wild type MIER1β GST-fusion proteins running around 125 kDa.  The lane-labeled GST 
does not contain a full length GST-fusion MIER1β protein, but the GST vector protein alone.  
The bottom arrow indicates the GST vector protein running around 26 kDa.  
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3.2 Full Length MIER1β Mutants YGY, MPI and FDP and Wild Type MIER1 Binding 
to H3K27ac 
  
 To determine whether the full length MIER1β mutants would bind H3K27ac, peptide pull 
down assays were completed using purified full length MIER1β mutant, and wild type GST-
fusion proteins (as described in section 3.1.2).  Peptide pull down assay have been described 
as a simple, and unbiased assay that allows for the identification of histone effector proteins, 
and various biotinylated histone peptides modified at particular residues.
111
  Utilizing this 
assay for our experiments allowed the results to be determined if there was a difference in 
binding between the full length wild type MIER1β protein, and the full length mutant 
MIER1β protein in an unbiased manner. 
  As a positive control for these assays wild type MIER1β protein was used since it is known 
to bind H3K27ac. (Paterno et al., unpublished)  The mutant and wild type proteins were 
independently incubated with, a biotin tagged H3K27ac peptide.  Then the protein-peptide 
complex was incubated with neutravidin conjugated beads eluted, and run on a SDS-PAGE 
gel.  The gels were then transferred to a PVDF membrane, and followed by Western Blot 
analysis with an Anti-GST antibody.  1µg for each GST-fusion protein was used in this assay, 
as shown on the Coomassie Blue stained SDS-page gel in Figure 3.4. 
 The initial peptide pull-down tested the full length MIER1β mutant Y73A, G74A, Y75A, 
and whether it could bind H3K27ac compared to the wild type protein.  The assays showed 
the full length mutant protein to have the same binding capability as wild type MIER1β.  
Therefore the chosen mutated amino acids were not the critical amino acids needed for 
binding (Figure 3.5A&3.5B).  The peptide pull down assay in Figure 3.5A&3.5B with the full 
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length Y73A, G74A, Y75A mutant, and wild type MIER1β was performed by Corinne Mercer 
(Terry Fox Lab, Division BioMedical Science, Faculty of Medicine, Memorial).   
 Next, another set of peptide pull down assays were completed to test the binding ability for 
the full length mutants M64A, P65A, I66A and F22A, D23A, P24A.  The alanine substitution 
for these conserved amino acids 
64
MPI
66
 and 
22
FDP
24 
also demonstrated the same binding 
capability as the wild type protein, and therefore they did not contain critical amino acids 
needed for binding despite being highly conserved against species (Figure 3.5C&3.5D).   
 These data show the three full length MIER1β mutants (YGY, MPI, and FDP) which have 
the same binding ability as the wild type MIER1β (Figure 3.5).  Therefore, the critical amino 
acids needed for binding H3K27ac. were not found in these amino acid sequences.  The 
peptide pull down assays were repeated three times in total for each full length mutant to, 
ensure reproducible results. 
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Figure 3.5: Full Length MIER1β Mutants YGY, MPI and FDP do not contain critical amino 
acids for binding 
 
Eluted GST fusion proteins were purified, bound to the biotinylated peptide and eluted 
according to the protocol in Material and Methods.  Eluted purified GST-fusion proteins were 
incubated separately overnight with a biotinylated H3K27ac peptide.  Then the protein-
peptide complex was incubated with avidin conjugated beads.  The protein-peptide bound 
complex was eluted by boiling with SSB loaded, and run on a SDS-PAGE gel.  It was then 
transferred to a PVDF membrane and a Western Blot analysis was conducted with an anti-
GST antibody to detect if any GST-tagged proteins had been pulled down.  Panel A depicts 
the (1/20
th
) input of the wild type and full length mutant YGY used to show the relative 
amount of eluted purified protein used, compared to the amount in the protein-peptide 
interaction as seen in panel B.  Panel C depicts the (1/20
th
) input of the wild type and full 
length mutants MPI and FDP used to show the relative amount of eluted purified protein 
compared to the amount used in the protein-peptide interaction as seen in panel D. 
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3.3 Creating MIER1 Deletion Constructs amino acids 1-63, 1-50 and 1-35 
 
 After site-directed mutagenesis in three different locations of conserved residues within 
MIER1β did not find the amino acids needed for binding, another approach was used to find 
the region that binds H3K27ac.  Instead of looking at the alignment of the first 83 amino acids 
(Figure 3.1), and selecting conserved amino acids that were hydrophobic with aromatic side 
chains, four smaller deletion constructs were made from amino acids 1-83.  This allowed us to 
try and narrow down, the area of known binding from 83 amino acids to a smaller area.  For 
each construct approximately every 15 amino acids from the C-terminal end were deleted in 
succession.  Deleting 15 amino acids from the C-terminal end to progressively make smaller 
construct, allowed me to examine smaller areas at time to determine if binding is occurring. If 
binding is occurring in a larger construct but not the progressively smaller construct then it 
would be likely that the binding sequence is located in between the two.  Care was taken not 
to delete part of a conserved sequence of aromatic, and hydrophobic amino acids.  For 
example, deletion construct aa 1-63 was not created as aa 1-65 (which would have been 
roughly 15 amino acids from amino acid 83) since amino acid 65 is in the middle of three 
conserved hydrophobic amino acids (amino acid sequence 64M,65P, 66I).  
The creation of four deletion constructs was attempted, starting with removing 
approximately 15 amino acids to create amino acids constructs 1-63, the 1-50, 1-35 and 1-19.  
We could not recover deletion construct 1-19 into the GST-vector, and so only constructs aa1-
63, 1-50 and 1-35 were prepared into GST-fusion proteins.  After they were PCR amplified 
(primers found in Table 2.4) from pcDNA3-MIER1β, the deletions were cloned into TOPO 
PCR2.1 vector.  The deletions were digested with EcoR1 and ligated into a GST tagged pGEX 
4T.1 vector at the EcoR1 site.   
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The GST-fusions proteins (deletion construct and GST-vector proteins) were prepared, 
purified and run on a SDS-PAGE gel with varying amounts of protein as in sections 2.5.1, and 
2.5.2.  Once each amount was determined to be around 1 µg, the chosen volume amount of 
GST-fusion protein for each deletion construct, and GST-vector alone was loaded onto a SDS-
PAGE gel stained with Coomassie Blue.  A diagram of the deletion constructs and GST-
vector used can be seen in Figure 3.6A, and the Coomassie stained gel can be seen in Figure 
3.6B. 
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Figure 3.6: Deletion Constructs of MIER1 
 Panel A. This diagram represents GST deletion constructs.  The GST tag is depicted on 
each deletion construct and then the GST tagged vector by itself.  The numbers of amino acids 
in each respective construct are indicated on the right of each construct. Panel B. GST fusion 
proteins were prepared as described in Material and Methods.  Around 1µg of deletion 
construct GST-fusion proteins were purified by binding to Glutathione Hi-Cap Matrix beads 
(Qiagen, cat# 30900), then eluted from the beads and run on a SDS-PAGE gel. The gel was 
then stained with Coomassie Blue and dried down.  The lane labeled GST does not contain a 
full length GST-fusion deletion construct protein but the GST vector protein alone.  Arrows 
indicate the band of interest for each of the deletion construct and GST-vector proteins.  
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3.4    Deletion Constructs 1-63 and 1-50 Bind H3K27ac but not Deletion Construct 1-35 
 Previous studies conducted by other individuals in the lab indicated that the first 83 amino 
acids of MIER1 bind H3K27ac.  Peptide pull-down assays were performed with deletion 
constructs to further narrow down the area where the binding site is located in MIER1β.  
Purified deletion constructs and GST-vector proteins were incubated, with a biotin-tagged 
H3K27ac peptide.  The protein-peptide complexes were pulled down with avidin conjugated 
beads, eluted and run onto a SDS-PAGE gel.  To analyze the pull-down samples the gels were 
transferred to a PVDF membrane, and subject to Western Blot analysis with an Anti-GST 
antibody.  Another deletion construct with amino acids 1-179 was used for a positive control 
in place of the construct 1-83 in each experiment, since it includes the known binding area to 
H3K27ac.  As a negative control GST-vector protein was also incubated with a biotin tagged 
H3K27ac peptide since, GST protein is known to not bind H3K27ac or unmodified H3 
(Paterno et al., unpublished).  The relative amounts of GST-fusion proteins were used in this 
assay and are shown on the Coomassie Blue stained SDS-PAGE gel in Figure 3.6.  These 
results were repeated twice more. 
 The peptide pull-down assay showed that the deletion amino acids constructs 1-63 and 1-
50 of MIER1 bound to H3K27ac. The deletion construct amino acids 1-35, however, did not 
bind, as seen in Figure 3.7. Since the construct 1-63, and 1-50 bound this suggests that amino 
acids 51-63 are not critically required for binding since the construct 1-50 bound to the 
peptide.  This suggests binding requires some or all of the amino acids 1-50.  The exact area 
needed for binding cannot be confirmed from these experiments since the deletions were only 
from the C-terminus, and deletion constructs that start at the N-terminus, and delete from the 
other end were not created.  To confirm if the 35-50 amino acids is critical sequence required 
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for binding, or if there is an amino acid located in 1-35 sequence that is also required for 
binding along with the amino acids 35-50, deletion constructs starting from the N-terminal 
end, similar to removing approximately 15 amino acids from the C-terminal of the first 83 
amino acids: 16-83, 30-83, 45-83 and 60-83 amino acid constructs should be made. Then test 
the constructs with peptide pull down assays to determine which sequence between the C-
terminal, and N-terminal deletions is necessary for binding the H3K27ac peptide.  
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Figure 3.7:  Deletion Constructs Amino Acids 1-63 and 1-50 Bind to H3K27ac but not 1-35 
 
Eluted deletion construct GST fusion proteins were purified, incubated with biotinylated 
peptide and eluted according to the protocol in Material and Methods.  Eluted purified GST-
fusion proteins were incubated separately overnight with a biotinylated H3K27ac peptide.  
Later they were incubated with neutravidin conjugated beads, and any protein-peptide bound 
complex was eluted by boiling with SSB, loaded, and run on a SDS-PAGE gel.  They were 
then transferred to a PVDF membrane and a Western Blot analysis was conducted with an 
Anti-GST antibody to detect if any GST-tagged proteins had been pulled down.  The (1/20
th
) 
input lane shows the relative amount of eluted purified protein compared to the amount used 
in the protein-peptide interaction. The GST vector lane acts as a control, since it has been 
shown to not bind with the peptide. 
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3.5 Full Length MIER1 Mutant TLE has Reduced Binding Compared to Wild Type 
MIER1 to H3K27ac 
 
 The results from the last section, testing binding of the amino acid deletion constructs 1-63, 
1-50 and 1-35, revealed that the binding requires some or all of the amino acids 35-50.  The 
next approach was to utilize the direct and fast method of site-directed mutagenesis, with three 
amino acids in MIER1β for H3K27ac.  The amino acid sequence 38TLE40 was chosen to 
mutate to all alanine amino acids by consulting the alignment diagram in Figure 3.1 because it 
was a conserved sequence between species, and the 
39
L is a hydrophobic acid which might be 
important in binding.  
 The same approach for creating all the full length mutants in T38A, L39A, E40A was 
implemented as that used in sections 3.1.1 and 3.1.2.  A restriction digest of the full length 
mutant T38A, L39A, E40A versus the wild type, shows an extra band in the mutant plasmid 
DNA for the Not1 site in the mutated DNA, along with the band from the cut at the Not1 site 
in the GST-vector (Figure 3.3).  The relative amount of GST-fusion protein concentration for 
the full length mutant T38A, L39A, E40A compared to the other full length mutants [Y73A, 
G74A, and Y75A], [M64, P65A, I66A] and [F22A, D23A, P24A], along with the wild type, 
and the GST protein by itself can be seen in Figure 3.4. 
 In order to determine if the full length mutant TLE contained the critical amino acids in 
MIER1β for binding of H3K27ac, peptide pull assays were performed.  As a positive control 
for this experiment, wild type MIER1β.  A negative control used for this experiment was the 
GST-vector.  Purified full length mutant 
38
TLE
40
, wild type, and GST-vector proteins were 
incubated with a biotin-tagged H3K27ac peptide.  The protein-peptide complex was then 
incubated with neutravidin conjugated beads, eluted and run on a SDS-PAGE gel.  To analyze 
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the pull downs, the gel was transferred to a PVDF membrane, followed by a Western Blot 
analysis with an Anti-GST antibody.  To verify binding capacity the TLE full length mutant, 
wild type MIER1β, and GST-vector proteins were also incubated with a biotin tagged  H3 
(21-44) peptide.  The protein-peptide complexes were incubated with neutravidin conjugated 
beads, eluted, run on the same SDS-page gel as the acetylated peptide bound protein 
complexes, and subjected to the same Western Blot conditions of the other samples in each 
experiment. These were chosen because the wild type MIER1β protein is known to bind 
H3K27ac but does not bind to the unmodified H3 peptide.  The GST protein was also known 
not to bind H3K27ac or unmodified H3 (Paterno et al. unpublished).  Each pull down was 
repeated three times with the same controls each time. 
 As evident in Figure 3.8, the peptide pull down assays illustrated that the full length mutant 
38
TLE
40
 had a reduced binding capability when compared to the binding of the wild type 
protein to H3K27ac.  This information indicates that the amino acids T38A, L39A, E40A, are 
important in the binding of H3K27ac, but, the T38A, L39A, E40A amino acid sequence is not 
the entire binding sequence.   
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Figure 3.8: Full Length MIER1β Mutant TLE Contains Critical Amino Acids for Binding 
H3K27ac 
 
Eluted GST fusion proteins were purified, bound to the biotinylated peptide and eluted 
according to the protocol in Material and Methods.  Eluted purified GST-fusion proteins were 
separately incubated overnight with a biotinylated H3K27ac peptide and H3 (21-44) peptide.  
Then the protein-peptide complex was incubated with neutravidin conjugated beads, and any 
protein-peptide bound complex was eluted by boiling with SSB, loaded and run on a SDS-
PAGE gel.  It was then transferred to a PVDF membrane and a Western Blot analysis was 
conducted with an anti-GST antibody to detect if any GST-tagged proteins had been pulled 
down.  Panel A depicts the (1/20
th
) input of the wild type.  Full length mutant TLE showed the 
relative amount of eluted purified protein, used compared to the amount in the protein-peptide 
interaction as seen in panel C.  Panel B depicts no binding of the GST-fusion proteins to the 
unmodified peptide H3 (21-44).  Panel C depicts the reduced binding capability of the full 
length TLE mutant compared to the wild type, and no binding of the GST-vector to the 
acetylated peptide. 
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Chapter 4- Discussion 
 
4.1 General Discussion 
 
 Lysine 27 on histone 3 (H3K27) plays a crucial role in the differentiation of ES cells.  
Depending on whether the residue is acetylated or methylated it allows for active or inactive 
gene transcription.
74
  In a recent study it was discovered that MIER1 recognizes, and binds to 
the acetylated residue of lysine 27 on histone 3 (Paterno et al., unpublished data).  Additional 
research has found that H3K27ac binds to MIER1 in the first 83 amino acids of the protein 
(Paterno et al., unpublished data).  The purpose of the present study was to determine the 
critical binding sequence in MIER1 for H3K27ac.  It is important to find and characterize the 
site at which H3K27ac, is binding to MIER1 since both of these modifications exert important 
functions in the cell.   
 Given the known role of MIER1 as a chromatin modifier, and its ability to bind an 
acetylated lysine, it can be assumed that the binding site in MIER1 for H3K27ac, would 
function in the same manner as other chromatin modifying proteins that bind acetylated 
lysines.  The purpose of this study was to determine the essential amino acids, in MIER1 that 
bind H3K27ac.   
 The initial full length mutant 
73-75
YGY (Y73A, G74A Y75A) was chosen because it had a 
strong sequence conservation of hydrophobic, and aromatic amino acids that have been shown 
previously to be directly involved in binding to a substrate.
56
  Importantly, in other studies of 
proteins binding acetylated histones, these conserved hydrophobic and aromatic amino acids 
were shown to be essential to the structure, and thus the function, of the protein.
56
  Perhaps, 
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one might assume that the mutation of these specific amino acids should change the relation of 
the secondary and tertiary structures formed by the protein binding to the acetylated lysine.  
However, this full length mutant had the same binding ability to H3K27ac as the full length 
wild type protein, as shown in peptide pull-down assays (Figure 3.5).  The other two full 
length mutants studied MPI (M64A, P65A, I66A), and FDP (F22A, D23A, P24A) had the 
same binding to H3K27ac as the full length wild type MIER1 GST-fusion protein.  This 
demonstrates that these conserved hydrophobic (P,I, and F), and aromatic (Y,F) amino acids 
do not play a role in the binding of H3K27ac to MIER1, nor the potential folded tertiary 
structure that the MIER1 protein forms to H3K27ac.  
 The next series of experiments used deletion constructs of the first 83 amino acids in 
MIER1 to examine a smaller region, which could contain the binding sequence to H3K27ac.  
Peptide pull-down assays with the three deletion constructs aa1-63, 1-50 and 1-35 were 
completed.  These studies revealed that amino acids from 1 to 50 were sufficient for the 
interaction with the H3K27ac peptide.  However, the deletion construct aa 1-35 did not bind to 
the H3K27ac peptide (Figure 3.7).   
 Approximately the same amount of protein for each of the deletion constructs (about 1µg) 
was used in the peptide pull down assays as shown in Figure 3.6.  However the equimolar 
amounts of the protein were not taken into account.  The differences in the molecular weights 
of each of the fusion proteins, and the amount of protein, should have been adjusted according 
to the largest molecular weight fusion construct (which would have been aa 1-179) so the 
same number of moles was used in each sample.  In future experiments I would digest all the 
deletion construct protein bands from an SDS-page gel then extract the peptides and run mass 
spectrometry on each sample to determine what amount was actually in each sample. 
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 The results from the last set of peptide pull-downs between the full length TLE mutant and 
the H3K27ac peptide revealed the full length mutant
38
TLE
40
 (T38A, L39A, and E40A) 
reduced the binding to H3K27ac compared to the full length wild type MIER1β GST-fusion 
protein (Figure 3.8).   
 MIER1 recognizes and binds to the acetylated modification on H3K27 (Paterno et al, 
unpublished data).  Thus we believe binding of H3K27ac to MIER1 is involved in its ability to 
act as a transcriptional repressor.  Initially, the hypothesis was that the binding site in MIER1 
was a conserved sequence of hydrophobic and aromatic amino acids.  This study 
demonstrated that the conserved amino acids in the 
38
TLE
40
 sequence is involved in the 
binding, but are not the only amino acids responsible for binding.
 
There are a couple of ways H3K27ac could be binding to MIER1.  One way maybe similar 
to that of the BRD protein which uses hydrophobic, and aromatic amino acids to form a 
binding pocket.  However, in the literature it has been shown there are other possible amino 
acids, and amino acid sequences sufficient for binding acetylated lysines. An arginine, 
asparagine, or acidic stretches of amino acids, including those in the SANT domain, could be 
involved in the docking to an acetylated histone. 
54,108,112–115
    
I found that while mutating the amino acids sequence 
38
TLE
40
 in the wild type protein to all 
alanines, and particularly mutating a conserved hydrophobic amino acid (
39
L) in the full 
length mutant MIER1 protein these three amino acids cannot account for total binding.  
However, the amino acids 
38
TLE
40
 are essential in contributing to binding.   It is likely that the 
binding site consists of several critical amino acids before the first 50 amino acids.  When the 
wild type MIER1 protein is folded into the proper binding conformation it could possibly use 
other amino acids, from down or upstream of the 
38
TLE
40
 sequence. 
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According to the literature, an arginine
108
 or asparagine
54,115
 might be required in the 
binding of proteins to acetylated lysines.  An arginine or asparagine could be involved in 
MIER1 binding to H3K27ac along with other hydrophobic aromatic amino acids, and/or the 
38
TLE
40
 amino acid sequence.  The method used in this study to determine the binding site 
was modeled after similar experiments with BRDs binding to acetylated substrates.  Some 
studies have found that along with the hydrophobic amino acids, BRDs require an arginine
108
 
or asparagine
54,115
 for completing the folded structure of the protein and the binding pocket.  
Therefore, it is possible that along with hydrophobic amino acids an arginine or asparagine is 
required for binding H3K27ac.  Interestingly, there is an arginine at 
37
R, and an asparagine at 
50
N.   Both of these are within the first 50 amino acids in MIER1, which I showed were 
required for H3K27ac binding in MIER1.   Either amino acid might be involved in binding 
and should be examined. 
Another acetylated lysine binding mechanism found in the literature, involves conserved 
acidic amino acid stretches.  A number of studies have shown that other acidic regions, or 
acidic activation domains, are involved in the binding of the acetylated substrates.  These 
acidic areas additionally have an affinity towards readers, and writers of acetylated lysines in 
various proteins suggesting a role in transcriptional regulation.
110-113
  For example, the tumor 
suppressor protein p53 that is known to bind acetylated lysines, contains an activation domain 
with several acidic amino acid residues that interact with different proteins such as Mouse 
double minute 2 homolog (Mdm2), and the CREB binding protein. 
116,117
  The ligand binding 
area in the secondary structure of p53’s  acidic transactivation domain has conserved 
hydrophobic amino acids in conserved positions that are critical to function of the protein.
116
  
Other examples of proteins that use acidic residues in transcriptional activity, include the 
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Epstein–Barr virus nuclear protein 2 (EBNA2), and herpes simplex virion protein 16 (VP16).   
They have also been shown to recruit, and bind the writer proteins p300/CBP using their 
acidic activation domains, and use the writers HAT domain in activating transcription.
112,116
  
The SANT domain which is often involved in protein-protein interactions, and can bind to 
histone tails to remodel nucleosomes, is covered in large areas of acidic residues.  These 
acidic patches have been proposed to act as binding locations for histone tails or highly basic 
proteins.
113
  While the SANT domain in MIER1, does not act in the binding of H3K27ac, the 
possibility that it serves another purpose in binding amino acid residues or other basic proteins 
is conceivable. (Paterno et al., unpublished) 
 Given that these examples of different proteins (p53, EBNA2 and VP16) use acidic amino 
acid stretches to bind acetylated substrates, along with their affinity towards different reader, 
and writer proteins and MIER1’s affinity towards similar readers and writers MIER1 may use 
one of the acidic stretches of amino acids starting at the 
40
E to bind H3K27ac.  Further 
characterization of amino acids upstream of 50 must be explored to determine if an arginine, 
asparagine, or a stretch of acidic amino acids is required in binding H3K27ac. 
 It is possible that the amino acids required for binding MIER1 to H3K27ac are in multiple 
locations, up or downstream, of the 
38
TLE
40
 sequence.  In 2006, Li et al.,
118
 determined that a 
a PHD finger of the human BPTF (bromodomain and PHD domain transcription factor) is 
required to bind to H3(1-15)K4me3.  This is the largest subunit of the ATP-dependent 
chromatin-remodeling complex, NURF.  They studied the binding site of the H3(1–
15)K4me3-peptide which was localized in the PHD domain using nuclear magnetic resonance 
(NMR).  The trimethylated lysine of K4 is positioned within a cage of four conserved 
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aromatic amino acids at different positions in the sequence of the domain. The amino acid 
3
Y 
forms the base, while 
10
Y, 
17
Y and 
32
W, form three walls.
118
   
 Furthermore, in 2003 Min et al.,
119
 used X-ray crystallography to generate a 1.4-Å-
resolution structure of the chromodomain in the Polycomb complex that was bound to a 
H3K27me3 peptide, in order to understand how the chromodomain in the protein was 
recognizing and binding to trimethyl modification.  The structure revealed a conserved model 
of methylated lysines in a crystal lattice, that is made up of conserved amino acids found in 
the chromodomains of the Polycomb protein family.  They looked at the similarities between 
the Drosophila Polycomb protein (dPC) with the H3K27me3 peptide compared to the HP1 
protein, and the H3K9me3 peptide.  Many features of the interactions between the dPC, and 
the H3K27me3 peptide were similar between the HP1 and H3K9m3 peptides.  Most 
importantly, they found that K27me3 is bound in a hydrophobic pocket made up of three 
aromatic residues, 
26
Y, 
47
W, and 
50
W similar to the K9me3 peptide.
119
  These findings further 
suggest that the binding site in MIER1 of H3K27ac might be at multiple highly conserved 
hydrophobic aromatic amino acids in different locations in the MIER1 amino acid sequence.  
When folded into the protein structure it creates a binding pocket. 
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4.2 Implications 
 
 The implications of determining the binding site of H3K27ac in MIER1 is significant and 
perhaps linked to the epigenetic regulation of gene expression.  Recent studies have found that 
loss of the acetylated H3K27 and particularly increased rates of trimethylated H3K27 by 
EZH2 has led to silencing of tumor suppressor genes and metastasis of different cancers.
120–122
 
An example of this is with ZEB1 induction, global H3K27ac levels are found to decrease 
while levels of methylation were found to be increased in ZEB1 genes located at H3K27.  
ZEB1 is an E-box binding transcription factor which is a major suppressor of epithelial genes 
in lung cancer. It is activated in cancer cells, and involved in invasion, metastasis, stem-like 
properties and it is a major factor in the chain of events leading to changes in gene expression 
during the epithelial to mesenchymal transition (EMT) in non-small cell lung cancer.  HDAC 
inhibitors were found to increase the expression of ZEB1 target genes.  Targeting these 
epigenetic modifications (ac and me3) would be expected to reduce metastasis.
120
  
 MIER1 binds to H3K27ac (Paterno et al., unpublished), and MIER1 has been shown to 
recruit HDAC1
93
 to enable deacetylation of H3K27 in target genes and which could lead to 
increased methylation these genes.  Thus, MIER1 could possibly be a marker for cancers with 
observed acetylated lysine loss with tri-methylated lysine gain.  This process could be enabled 
since MIER1 has been shown to block the HAT CBP from acetylating lysines, and recruit 
HDAC1 to remove the acetyl group from the lysine residue.
93
 (Paterno et al., unpublished 
data).  This then creates the opportunity for HMTs to add methyl groups to the lysine, marking 
it for transcriptional repression.  The only HMT to trimethylate H3K27 is the PRC2 complex 
via its EZH2 component.
78
  High levels of EZH2 in adults cells have been shown to lead to 
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poor prognosis in many cancers including prostate cancer, breast cancer, lymphoma, 
myeloma, colorectal cancer, endometrial cancer, bladder cancer and melanoma.
12,123
 
Currently, there are many therapeutic treatments being developed, and used in the clinic, that 
either target HDACs, or certain HMTs, such as EZH2.   
  MIER1 has been shown to interact with ERα, and over expression of MIER1 in invasive 
ductal carcinoma causes restriction of estrogen-stimulated anchorage-independent growth. 
91
  
The ERα receptor, along with similar hormone receptors such as estrogen-related receptor 
alpha (ERRα), are PTM to control gene regulation.  Specific lysine residues in DNA binding 
domain of ERRα can be acetylated by p300 coactivator associated factor (PCAF), and 
deacetylated by HDAC8.
124
  Given that MIER1 has been demonstrated to recruit, and block 
the HAT activity of p300/CBP, it is possible that MIER1 can exert the same affinity towards a 
similar reader protein, PCAF to control acetyl activity.
95
   Also given the knowledge that 
MIER1 interacts with ERα, and other nuclear receptors, it should be investigated if MIER1 
associates with ERRα to possibly control breast cancer progression.91 
 In view of the fact that MIER1 is a known chromatin modifier and repressor of 
transcription
93,95
(Paterno et al., unpublished), and since H3K27 PTMs have been found in 
many aggressive cancers, it would be logical to investigate treatments involving MIER1 
bound complexes.  This could include MIER1 and HDAC in a complex together.  Recently, 
Millard et al., (2013) studied HDACs in complexes with chromatin modifiers for the purpose 
developing inhibtors.
31
  They found HDACs are often found in repressor complexes, so it is 
reasonable to develop inhibitors for this complex.  In the same paper, the ELM2 and SANT 
domains are shown to act together by completely wrapping around HDAC, covering the active 
sites and allowing other domains to recruit nucleosomes to the complex.  Often ELM2 and 
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SANT domains are juxtaposed in co-repressor proteins suggesting a conserved function, and 
most of these proteins have been shown to recruit HDAC1 and/or HDAC2.
31
  MIER1 recruits 
HDAC1/2 through its ELM2 domain.  While there is no known function yet involving both 
the ELM2 and SANT domain in MIER1, given conservation, a function is likely for both 
domains.  The SANT domain in MIER1 is known to repress transcription of Sp1 at MIER1’s 
promoter and has been shown to interact with the HMT G9a.
93,94
 Once again this suggests 
there is a functional relationship between the two domains, potentially when MIER1 is bound 
to H3K27ac and must recruit other chromatin modifiers in order to alter the acetylated active 
state of the chromatin to trimethylate and inactive H3K27 bound genes.  Thus, developing 
inhibitors of HDAC1s ability to form in a complex with MIER1 might be a viable drug 
treatment.  If MIER1 could not bind HDAC then this would lessen the capacity of HDAC to 
remove the acetyl group.  This would then lead to less unmodified H3K27 available.  Also 
there would be less amounts of inactive chromatin that might be targeted by aberrant EZH2 
activity, thus making the chromatin available for active transcription. 
 The role of MIER1 in epigenetic regulation has only been studied with MIER1 GST-fusion 
proteins and cell lines.  Also MIER1 has only recently been found to bind to H3K27ac in vitro 
using protein samples.(Paterno et al., unpublished)  Originally however, the function of 
MIER1 was first investigated in the developing embryo, and was found to be upregulated after 
the induction of mesoderm differentiation by FGFs during early embryo develop in Xmier1, 
then undetectable in the following developing stages.
87
  It should be investigated in embryonic 
stem cells (ES) if there is a link to genes associated with modified H3K27 that are involved in 
recruitment of tissue-specific transcription factors, which lead to the establishment of tissue-
specific gene expression pattern in embryos.  Especially since both PTM acetylation and 
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methylation have been shown to have important impacts on H3K27 bound genes.  
Particularly, acetylation of H3K27 has been shown to be associated with the trithorax protein 
which is responsible for the maintenance of gene expression.
73
  Also the trimethylation of 
lysine 27 is a target for the PRC2 complex at specific areas that are marked for early 
embryogenesis. Given this information, it is possible that MIER1 exerts a different function as 
a transcriptional regulator in those genes during development depending on whether they are 
acetylated or methylated, and should be investigated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
83 
 
4.3 Future Studies 
 
 While much progress has been made in narrowing down the critical binding site in MIER1 
for H3K27ac, more work is necessary to determine the exact binding sequence.  Once the 
binding site has been located in MIER1, the potential to uncover the precise function of 
MIER1 when bound to H3K27ac associated genes can be further characterized.  When this 
site has been extensively studied, the potential for MIER1 as a chromatin modifier may serve 
as a therapeutic aid for certain cancers.  Below are some of the experiments that can be 
completed in order to further understand the mechanism of MIER1 activity in the cell. 
 
4.3.1 Determine Binding site in MIER1 of H3K27ac 
 
 As mentioned in the results, it would be worthwhile to further narrow down the sequence in 
MIER1 that binds H3K27ac.  The optimal way to determine this interaction site would be to 
create deletion constructs from amino acids 1-83.  Using the strategy outlined here, four 
deletion constructs could be produced that progressively remove 15 amino acids.   However, 
instead of deleting from the C-terminal end, the process could start by deleting from the N-
terminal end of MIER1.  Deleting about 15 amino acids at a time (amino acids: 16-83, 30-83, 
45-83 and 60-83) allows for a broader region to be tested for the binding location of H3K27ac.  
Then, depending on the results of those experiments compared to the sequence know from this 
study (aa 36-50) it can be defined to an exact sequence of amino acids.  A peptide pull down 
array could be performed to observe which amino acids in the deletion constructs are 
interacting with the acetylated H3K27 peptide.  Deletion constructs containing amino acids 
16-83, 30-83 and 45-83 should be particularly useful.   
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4.3.2 Determine exact amino acids required for binding of H3K27ac in MIER1 
 
 Once the essential region in MIER1 has been determined through the use of deletion 
constructs, site directed mutagenesis of conserved amino acids in the that region could be the 
best way to create a full length MIER1 that is not capable of binding H3K27ac.  Once the full 
length MIER1 mutant protein is produced, the mutant should be tested against the wild type 
full length MIER1 in a peptide pull down assay to confirm that it does not bind the H3K27ac 
peptide.   
 
4.3.3 Characterize the binding site in MIER1 of H3K27ac  
 
 To fully understand what is happening when MIER1 is binding H3K27ac, the MIER1 site 
needs to be characterized.  Once the binding amino acid sequence has been determined in 
MIER1 for H3K27ac, the structural basis of how the binding is occurring can be studied.  
Using X-Ray crystallography, the sequence in MIER1 that binds H3K27ac can be visualized, 
and how the protein folds and where the modification interacts with the protein can be further 
studied.  The purified MIER1 protein deletion construct of amino acids 1-83 (with the GST-
tag digested) should be used to crystallize with the H3K27ac (21-43) peptide since it contains 
the binding site and encompasses the entire sequence known to bind the peptide. 
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4.3.4 Demonstrate an in vivo effect on adult cells with Mutant MIER1  
 
 The physiological effect of having a full length mutant MIER1 that cannot bind to 
acetylated H3K27 in healthy breast epithelial cells could be studied.  A method to test this 
would be to transfect a full length mutant MIER1 plasmid, into the epithelial breast cells.  
Then the cells should be studied to see if there are any physiological changes. Ultimately we 
want to determine what effects MIER1 has in regulating H3K27 associated genes, and in turn, 
cancer progression.  So it should also be determined whether there is an increase in growth or 
any other physiological changes to the normal breast cells that would be indicative of changes 
in cancerous growth. 
 
4.3.5 Determine any role MIER1 has on cells during development associated to H3K27 
regulated genes 
 
 MIER1 was first discovered as a fibroblast growth factor activated early response gene.  
The expression levels of Xmier1 were up-regulated after the induction of mesoderm 
differentiation by FGFs.
90
  It has been demonstrated  in the literature that early developmental 
cues are epigenetically pre-marked in human ES cells, and indicate the different roles of 
H3K27me3 and H3K27ac as regulatory elements in the early stages of human 
embryogenesis.
69
  As the GST-protein of MIER1 has only been shown to bind H3K27ac, it 
would be interesting to determine if it might be linked to genes that are active in ES cells.   
These would include the trithorax protein (MLL, the human homolog), which is responsible 
for the maintenance of gene expression of  acetylated H3K27 target genes.
73
  This is 
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especially interesting because trithorax associates with CBP, and is required for the 
maintenance of transcriptionally active states that repress Polycomb silencing.  Because 
MIER1 is known to recruit chromatin modifiers and transcription factors in adult cells
93–
96
(Paterno et al., unpublished), it should be studied if MIER1 is exerting a vital role 
development and differentiation of ES cells.  A chromatin immunoprecipitation on ChIP 
(ChIP on chIP) could be performed to determine if in MIER1 there are H3K27 associated 
genes binding in the promoters, enhancers or repressor regions of assocaited genes.  Then, to 
determine if MIER1 is being recruited to modify tissue-specific transcription factors, a 
transgenic reporter assay in mice embryos could be performed to determine cell-type and 
stage-specific expression characteristic of developmental genes. 
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